2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ponikowski, 2016, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur Heart J, 37, 2129, 10.1093/eurheartj/ehw128
Piepoli, 2016, 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), Eur Heart J, 37, 2315, 10.1093/eurheartj/ehw106
Ibanez, 2018, 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC), Eur Heart J, 39, 119, 10.1093/eurheartj/ehx393
Williams, 2018, 2018 ESC/ESH Guidelines for the management of arterial hypertension, Eur Heart J, 39, 3021, 10.1093/eurheartj/ehy339
Knuuti, 2020, 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes, Eur Heart J, 41, 407, 10.1093/eurheartj/ehz425
Cosentino, 2020, 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD, Eur Heart J, 41, 255, 10.1093/eurheartj/ehz486
Hindricks, 2021, 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS, Eur Heart J, 42, 373, 10.1093/eurheartj/ehaa612
Lund, 2018, Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum, Eur J Heart Fail, 20, 1230, 10.1002/ejhf.1149
Solomon, 2016, Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction, Eur Heart J, 37, 455, 10.1093/eurheartj/ehv464
Abdul-Rahim, 2018, VICCTA-Heart Failure Collaborators. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction, Eur J Heart Fail, 20, 1139, 10.1002/ejhf.1160
Cleland, 2006, The perindopril in elderly people with chronic heart failure (PEP-CHF) study, Eur Heart J, 27, 2338, 10.1093/eurheartj/ehl250
Cleland, 2018, Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials, Eur Heart J, 39, 26, 10.1093/eurheartj/ehx564
Solomon, 2019, Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction, N Engl J Med, 381, 1609, 10.1056/NEJMoa1908655
Lam, 2020, Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction, Eur Heart J, 41, 2353, 10.1093/eurheartj/ehaa158
Bozkurt, 2021, Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association, Eur J Heart Fail, 23, 352, 10.1002/ejhf.2115
Galderisi, 2017, Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging, Eur Heart J Cardiovasc Imaging, 18, 1301, 10.1093/ehjci/jex244
Arrigo, 2019, Right ventricular failure: pathophysiology, diagnosis and treatment, Card Fail Rev, 5, 140, 10.15420/cfr.2019.15.2
Gorter, 2018, Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 20, 16, 10.1002/ejhf.1029
Caraballo, 2019, Clinical implications of the New York Heart Association classification, J Am Heart Assoc, 8, e014240, 10.1161/JAHA.119.014240
Solomon, 2016, Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial, JACC Heart Fail, 4, 816, 10.1016/j.jchf.2016.05.002
Conrad, 2018, Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals, Lancet, 391, 572, 10.1016/S0140-6736(17)32520-5
Dunlay, 2014, Understanding the epidemic of heart failure: past, present, and future, Curr Heart Fail Rep, 11, 404, 10.1007/s11897-014-0220-x
Roth, 2015, Demographic and epidemiologic drivers of global cardiovascular mortality, N Engl J Med, 372, 1333, 10.1056/NEJMoa1406656
Savarese, 2017, Global public health burden of heart failure, Card Fail Rev, 3, 7, 10.15420/cfr.2016:25:2
Meyer, 2015, Sex differences in new-onset heart failure, Clin Res Cardiol, 104, 342, 10.1007/s00392-014-0788-x
Brouwers, 2013, Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND, Eur Heart J, 34, 1424, 10.1093/eurheartj/eht066
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, 2018, Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet, 392, 1789, 10.1016/S0140-6736(18)32279-7
Smeets, 2019, Burden of heart failure in Flemish general practices: a registry-based study in the Intego database, BMJ Open, 9, e022972, 10.1136/bmjopen-2018-022972
Virani, 2020, Heart disease and stroke statistics---2020 update: a report from the American Heart Association, Circulation, 141, e139, 10.1161/CIR.0000000000000757
van Riet, 2014, Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion, Eur J Heart Fail, 16, 772, 10.1002/ejhf.110
van Riet, 2016, Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review, Eur J Heart Fail, 18, 242, 10.1002/ejhf.483
Benjamin, 2018, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics---2018 update: a report from the American Heart Association, Circulation, 137, e67, 10.1161/CIR.0000000000000558
Ceia, 2002, Prevalence of chronic heart failure in Southwestern Europe: the EPICA study, Eur J Heart Fail, 4, 531, 10.1016/S1388-9842(02)00034-X
Bibbins-Domingo, 2009, Racial differences in incident heart failure among young adults, N Engl J Med, 360, 1179, 10.1056/NEJMoa0807265
Bleumink, 2004, Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study, Eur Heart J, 25, 1614, 10.1016/j.ehj.2004.06.038
Koh, 2017, A comprehensive population-based characterization of heart failure with mid-range ejection fraction, Eur J Heart Fail, 19, 1624, 10.1002/ejhf.945
Chioncel, 2017, Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry, Eur J Heart Fail, 19, 1574, 10.1002/ejhf.813
Shah, 2009, Heart failure in women: epidemiology, biology and treatment, Womens Health (Lond), 5, 517, 10.2217/WHE.09.50
Roger, 2004, Trends in heart failure incidence and survival in a community-based population, JAMA, 292, 344, 10.1001/jama.292.3.344
Vedin, 2017, Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study, Circ Heart Fail, 10, 10.1161/CIRCHEARTFAILURE.117.003875
Kapoor, 2016, Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction, JACC Heart Fail, 4, 464, 10.1016/j.jchf.2016.02.017
Heiat, 2002, Representation of the elderly, women, and minorities in heart failure clinical trials, Arch Intern Med, 162, 1682, 10.1001/archinte.162.15.1682
Gerber, 2015, A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010, JAMA Intern Med, 175, 996, 10.1001/jamainternmed.2015.0924
Tsao, 2018, Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction, JACC Heart Fail, 6, 678, 10.1016/j.jchf.2018.03.006
Motiejunaite, 2020, The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions, Eur Heart J, 41, 1357, 10.1093/eurheartj/ehaa071
Dunlay, 2012, Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction, Circ Heart Fail, 5, 720, 10.1161/CIRCHEARTFAILURE.111.966366
Clarke, 2013, Natural history of left ventricular ejection fraction in patients with heart failure, Circ Cardiovasc Qual Outcomes, 6, 680, 10.1161/CIRCOUTCOMES.111.000045
Tsuji, 2017, CHART-2 Investigators. Characterization of heart failure patients with mid-range left ventricular ejection fraction--a report from the CHART-2 Study, Eur J Heart Fail, 19, 1258, 10.1002/ejhf.807
Rastogi, 2017, Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction, Eur J Heart Fail, 19, 1597, 10.1002/ejhf.879
Lupon, 2018, Bayes-Genis A. Dynamic trajectories of left ventricular ejection fraction in heart failure, J Am Coll Cardiol, 72, 591, 10.1016/j.jacc.2018.05.042
Pocock, 2013, Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies, Eur Heart J, 34, 1404, 10.1093/eurheartj/ehs337
Barasa, 2014, Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden, Eur Heart J, 35, 25, 10.1093/eurheartj/eht278
Jhund, 2009, Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people, Circulation, 119, 515, 10.1161/CIRCULATIONAHA.108.812172
Dunlay, 2009, Hospitalizations after heart failure diagnosis a community perspective, J Am Coll Cardiol, 54, 1695, 10.1016/j.jacc.2009.08.019
Taylor, 2019, Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study, BMJ, 364, l223, 10.1136/bmj.l223
Lorenzoni, 2018, Time trends in first hospitalization for heart failure in a community-based population, Int J Cardiol, 271, 195, 10.1016/j.ijcard.2018.05.132
Mosterd, 2002, Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic?, Heart, 87, 75, 10.1136/heart.87.1.75
Chen, 2013, National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998-2010, Circulation, 128, 2577, 10.1161/CIRCULATIONAHA.113.003668
Lawson, 2019, 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study, Lancet Public Health, 4, e406, 10.1016/S2468-2667(19)30108-2
Al-Mohammad, 2010, Diagnosis and management of adults with chronic heart failure: summary of updated NICE guidance, BMJ, 341, c4130, 10.1136/bmj.c4130
Mant, 2009, Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care, Health Technol Assess, 13, 1, 10.3310/hta13320
Davie, 1997, Assessing diagnosis in heart failure: which features are any use?, QJM, 90, 335, 10.1093/qjmed/90.5.335
Oudejans, 2011, Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests, Eur J Heart Fail, 13, 518, 10.1093/eurjhf/hfr021
Kelder, 2011, The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure, Circulation, 124, 2865, 10.1161/CIRCULATIONAHA.111.019216
Thibodeau, 2014, Characterization of a novel symptom of advanced heart failure: bendopnea, JACC Heart Fail, 2, 24, 10.1016/j.jchf.2013.07.009
Gohar, 2019, Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure, Eur J Heart Fail, 21, 1219, 10.1002/ejhf.1495
Hildebrandt, 2008, Amino-terminal pro-B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients, Am J Cardiol, 101, 25, 10.1016/j.amjcard.2007.11.016
Maisel, 2008, State of the art: using natriuretic peptide levels in clinical practice, Eur J Heart Fail, 10, 824, 10.1016/j.ejheart.2008.07.014
Lancellotti, 2017, Echo-Doppler estimation of left ventricular filling pressure: results of the multicentre EACVI Euro-Filling study, Eur Heart J Cardiovasc Imaging, 18, 961, 10.1093/ehjci/jex067
Gardner, 2003, N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure, Eur Heart J, 24, 1735, 10.1016/j.ehj.2003.07.005
Roberts, 2015, The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting, BMJ, 350, h910, 10.1136/bmj.h910
Mueller, 2019, Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations, Eur J Heart Fail, 21, 715, 10.1002/ejhf.1494
Madamanchi, 2014, Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure, Int J Cardiol, 176, 611, 10.1016/j.ijcard.2014.08.007
Cowie, 1997, Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care, Lancet, 350, 1349, 10.1016/S0140-6736(97)06031-5
Zaphiriou, 2005, The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study, Eur J Heart Fail, 7, 537, 10.1016/j.ejheart.2005.01.022
Kelder, 2011, Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure, J Card Fail, 17, 729, 10.1016/j.cardfail.2011.04.013
Verdu, 2012, Rapid point-of-care NT-proBNP optimal cut-off point for heart failure diagnosis in primary care, Rev Esp Cardiol (Engl Ed), 65, 613
Taylor, 2017, Primary care REFerral for EchocaRdiogram (REFER) in heart failure: a diagnostic accuracy study, Br J Gen Pract, 67, e94, 10.3399/bjgp16X688393
Sicari, 2009, Stress Echocardiography Expert Consensus Statement--Executive Summary: European Association of Echocardiography (EAE) (a registered branch of the ESC), Eur Heart J, 30, 278, 10.1093/eurheartj/ehn492
Lancellotti, 2016, The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography, Eur Heart J Cardiovasc Imaging, 17, 1191, 10.1093/ehjci/jew190
Gonzalez, 2015, Role of imaging techniques for diagnosis, prognosis and management of heart failure patients: cardiac magnetic resonance, Curr Heart Fail Rep, 12, 276, 10.1007/s11897-015-0261-9
Messroghli, 2017, Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2 and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI), J Cardiovasc Magn Reson, 19, 75, 10.1186/s12968-017-0389-8
Witteles, 2019, Screening for transthyretin amyloid cardiomyopathy in everyday practice, JACC Heart Fail, 7, 709, 10.1016/j.jchf.2019.04.010
Gupta, 2015, Natriuretic peptides and cardiometabolic health, Circ J, 79, 1647, 10.1253/circj.CJ-15-0589
Zois, 2014, Natriuretic peptides in cardiometabolic regulation and disease, Nat Rev Cardiol, 11, 403, 10.1038/nrcardio.2014.64
Nishikimi, 2011, Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides, J Cardiol, 57, 131, 10.1016/j.jjcc.2011.01.002
Velazquez, 2011, Coronary-artery bypass surgery in patients with left ventricular dysfunction, N Engl J Med, 364, 1607, 10.1056/NEJMoa1100356
Allman, 2002, Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis, J Am Coll Cardiol, 39, 1151, 10.1016/S0735-1097(02)01726-6
Ling, 2013, Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium, Circ Cardiovasc Imaging, 6, 363, 10.1161/CIRCIMAGING.112.000138
Bonow, 2011, Myocardial viability and survival in ischemic left ventricular dysfunction, N Engl J Med, 364, 1617, 10.1056/NEJMoa1100358
Panza, 2019, Myocardial viability and long-term outcomes in ischemic cardiomyopathy, N Engl J Med, 381, 739, 10.1056/NEJMoa1807365
Corra, 2014, Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role: a position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the ESC, Eur J Heart Fail, 16, 929, 10.1002/ejhf.156
Piepoli, 2011, Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation, Eur J Heart Fail, 13, 347, 10.1093/eurjhf/hfr017
Corra, 2018, Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 20, 3, 10.1002/ejhf.979
Cooper, 2007, The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology, Eur Heart J, 28, 3076, 10.1093/eurheartj/ehm456
Cooper, 1997, Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators, N Engl J Med, 336, 1860, 10.1056/NEJM199706263362603
Lang, 2015, Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, Eur Heart J Cardiovasc Imaging, 16, 233, 10.1093/ehjci/jev014
Gheorghiade, 2013, Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives, Heart Fail Clin, 9, 285, 10.1016/j.hfc.2013.05.002
Ambrosy, 2014, The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries, J Am Coll Cardiol, 63, 1123, 10.1016/j.jacc.2013.11.053
Anker, 2016, Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency, Eur J Heart Fail, 18, 482, 10.1002/ejhf.516
Gayat, 2018, Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study, Eur J Heart Fail, 20, 345, 10.1002/ejhf.932
Crespo-Leiro, 2016, European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions, Eur J Heart Fail, 18, 613, 10.1002/ejhf.566
McMurray, 2014, Angiotensin-neprilysin inhibition versus enalapril in heart failure, N Engl J Med, 371, 993, 10.1056/NEJMoa1409077
Velazquez, 2019, Angiotensin-neprilysin inhibition in acute decompensated heart failure, N Engl J Med, 380, 539, 10.1056/NEJMoa1812851
Wachter, 2019, Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study, Eur J Heart Fail, 21, 998, 10.1002/ejhf.1498
McMurray, 2019, Dapagliflozin in patients with heart failure and reduced ejection fraction, N Engl J Med, 381, 1995, 10.1056/NEJMoa1911303
Packer, 2020, Cardiovascular and renal outcomes with empagliflozin in heart failure, N Engl J Med, 383, 1413, 10.1056/NEJMoa2022190
1987, The CONSENSUS Trial Study Group. Enalapril for congestive heart failure, N Engl J Med, 317, 1349, 10.1056/NEJM198711193172112
Garg, 1995, Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials, JAMA, 273, 1450, 10.1001/jama.1995.03520420066040
Packer, 1999, Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group, Circulation, 100, 2312, 10.1161/01.CIR.100.23.2312
SOLVD, 1991, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501
MERIT-HF Study Group, 1999, Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2
Packer, 1996, The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group, N Engl J Med, 334, 1349, 10.1056/NEJM199605233342101
Packer, 2001, Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure, N Engl J Med, 344, 1651, 10.1056/NEJM200105313442201
Hjalmarson, 2000, Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group, JAMA, 283, 1295, 10.1001/jama.283.10.1295
Packer, 2002, Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study, Circulation, 106, 2194, 10.1161/01.CIR.0000035653.72855.BF
Flather, 2005, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS, Eur Heart J, 26, 215, 10.1093/eurheartj/ehi115
CIBIS-II Investigators and Committees, 1999, The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet, 353, 9, 10.1016/S0140-6736(98)11181-9
Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001
Zannad, 2011, Eplerenone in patients with systolic heart failure and mild symptoms, N Engl J Med, 364, 11, 10.1056/NEJMoa1009492
Fowler, 1997, Effects of beta blockers on symptoms and functional capacity in heart failure, Am J Cardiol, 80, 55L, 10.1016/S0002-9149(97)00849-7
Willenheimer, 2005, Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III, Circulation, 112, 2426, 10.1161/CIRCULATIONAHA.105.582320
Kotecha, 2014, Beta-Blockers in Heart Failure Collaborative Group. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis, Lancet, 384, 2235, 10.1016/S0140-6736(14)61373-8
Seferovic, 2017, Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial, Lancet Diabetes Endocrinol, 5, 333, 10.1016/S2213-8587(17)30087-6
Damman, 2018, Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure, JACC Heart Fail, 6, 489, 10.1016/j.jchf.2018.02.004
Desai, 2017, Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF Trial, JAMA Cardiol, 2, 79, 10.1001/jamacardio.2016.4733
Vardeny, 2019, Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial, Eur J Heart Fail, 21, 337, 10.1002/ejhf.1402
Vardeny, 2018, Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure, Circ Heart Fail, 11, 10.1161/CIRCHEARTFAILURE.117.004745
Morrow, 2019, Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial, Circulation, 139, 2285, 10.1161/CIRCULATIONAHA.118.039331
Kosiborod, 2020, Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial, Circulation, 141, 90, 10.1161/CIRCULATIONAHA.119.044138
Butler, 2021, EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial, Eur Heart J, 42, 1203, 10.1093/eurheartj/ehaa1007
Zannad, 2020, SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, Lancet, 396, 819, 10.1016/S0140-6736(20)31824-9
Jackson, 2020, Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF, Circulation, 142, 1040, 10.1161/CIRCULATIONAHA.120.047077
Bhatt, 2021, SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure, N Engl J Med, 384, 117, 10.1056/NEJMoa2030183
Faris, 2002, Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials, Int J Cardiol, 82, 149, 10.1016/S0167-5273(01)00600-3
Granger, 2003, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial, Lancet, 362, 772, 10.1016/S0140-6736(03)14284-5
Swedberg, 2010, Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study, Lancet, 376, 875, 10.1016/S0140-6736(10)61198-1
Swedberg, 2012, Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study, J Am Coll Cardiol, 59, 1938, 10.1016/j.jacc.2012.01.020
Armstrong, 2020, Vericiguat in patients with heart failure and reduced ejection fraction, N Engl J Med, 382, 1883, 10.1056/NEJMoa1915928
Taylor, 2004, Combination of isosorbide dinitrate and hydralazine in blacks with heart failure, N Engl J Med, 351, 2049, 10.1056/NEJMoa042934
Cohn, 1986, Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study, N Engl J Med, 314, 1547, 10.1056/NEJM198606123142404
Digitalis Investigation Group, 1997, The effect of digoxin on mortality and morbidity in patients with heart failure, N Engl J Med, 336, 525, 10.1056/NEJM199702203360801
Mullens, 2019, The use of diuretics in heart failure with congestion -- a position statement from the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 21, 137, 10.1002/ejhf.1369
Rohde, 2019, Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial, Eur Heart J, 40, 3605, 10.1093/eurheartj/ehz554
Cohn, 2001, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med, 345, 1667, 10.1056/NEJMoa010713
Bohm, 2013, Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study, Clin Res Cardiol, 102, 11, 10.1007/s00392-012-0467-8
Ouyang, 2015, Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation, Am J Cardiol, 115, 901, 10.1016/j.amjcard.2015.01.013
Vamos, 2015, Digoxin-associated mortality: a systematic review and meta-analysis of the literature, Eur Heart J, 36, 1831, 10.1093/eurheartj/ehv143
Ziff, 2015, Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data, BMJ, 351, h4451, 10.1136/bmj.h4451
Van Gelder, 2010, Lenient versus strict rate control in patients with atrial fibrillation, N Engl J Med, 362, 1363, 10.1056/NEJMoa1001337
Bavishi, 2015, Digoxin in patients with atrial fibrillation and heart failure: a meta-analysis, Int J Cardiol, 188, 99, 10.1016/j.ijcard.2015.04.031
Freeman, 2015, Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study, Circ Arrhythm Electrophysiol, 8, 49, 10.1161/CIRCEP.114.002292
Rathore, 2003, Association of serum digoxin concentration and outcomes in patients with heart failure, JAMA, 289, 871, 10.1001/jama.289.7.871
Adams, 2005, Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group trial: a retrospective analysis, J Am Coll Cardiol, 46, 497, 10.1016/j.jacc.2005.02.091
Bavendiek, 2019, Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study, Eur J Heart Fail, 21, 676, 10.1002/ejhf.1452
Teerlink, 2021, Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure, N Engl J Med, 384, 105, 10.1056/NEJMoa2025797
Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, McMurray JJV., 2017, Declining risk of sudden death in heart failure, N Engl J Med, 377, 41, 10.1056/NEJMoa1609758
Bardy, 2005, Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure, N Engl J Med, 352, 225, 10.1056/NEJMoa043399
Connolly, 2000, investigators of the AVID, CASH and CIDS studies. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials, Eur Heart J, 21, 2071, 10.1053/euhj.2000.2476
Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators, 1997, A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias, N Engl J Med, 337, 1576, 10.1056/NEJM199711273372202
Kuck, 2000, Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH), Circulation, 102, 748, 10.1161/01.CIR.102.7.748
Moss, 2002, Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction, N Engl J Med, 346, 877, 10.1056/NEJMoa013474
Kober, 2016, Defibrillator implantation in patients with nonischemic systolic heart failure, N Engl J Med, 375, 1221, 10.1056/NEJMoa1608029
Beggs, 2018, Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis, Heart, 104, 144, 10.1136/heartjnl-2016-310850
Merchant, 2014, Incidence of defibrillator shocks after elective generator exchange following uneventful first battery life, J Am Heart Assoc, 3, e001289, 10.1161/JAHA.114.001289
Yap, 2014, Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate ICD therapy, Heart, 100, 1188, 10.1136/heartjnl-2014-305535
Kini, 2014, Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met?, J Am Coll Cardiol, 63, 2388, 10.1016/j.jacc.2014.03.025
Erkapic, 2013, Long-term benefit of implantable cardioverter/defibrillator therapy after elective device replacement: results of the INcidence free SUrvival after ICD REplacement (INSURE) trial--a prospective multicentre study, Eur Heart J, 34, 130, 10.1093/eurheartj/ehs177
Alsheikh-Ali, 2008, Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy, J Cardiovasc Electrophysiol, 19, 784, 10.1111/j.1540-8167.2008.01111.x
Opreanu, 2015, Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: a national database analysis, J Heart Lung Transplant, 34, 1305, 10.1016/j.healun.2015.04.004
Zishiri, 2013, Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator, Circ Arrhythm Electrophysiol, 6, 117, 10.1161/CIRCEP.112.973552
Kutyifa, 2015, Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry), Circulation, 132, 1613, 10.1161/CIRCULATIONAHA.115.015677
Kutyifa, 2018, One-year follow-up of the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry), Pacing Clin Electrophysiol, 41, 1307, 10.1111/pace.13448
Hohnloser, 2004, Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction, N Engl J Med, 351, 2481, 10.1056/NEJMoa041489
Steinbeck, 2009, Defibrillator implantation early after myocardial infarction, N Engl J Med, 361, 1427, 10.1056/NEJMoa0901889
Sanders, 2005, Cost-effectiveness of implantable cardioverter-defibrillators, N Engl J Med, 353, 1471, 10.1056/NEJMsa051989
Steinberg, 2014, Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials, JACC Heart Fail, 2, 623, 10.1016/j.jchf.2014.06.007
Raphael, 2015, The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?, Eur Heart J, 36, 1676, 10.1093/eurheartj/ehv102
Miller, 2015, Baseline functional class and therapeutic efficacy of common heart failure interventions: a systematic review and meta-analysis, Can J Cardiol, 31, 792, 10.1016/j.cjca.2014.12.031
Hess, 2015, Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials, Circ Cardiovasc Qual Outcomes, 8, 179, 10.1161/CIRCOUTCOMES.114.001306
Connolly, 2000, Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone, Circulation, 101, 1297, 10.1161/01.CIR.101.11.1297
Kober, 2008, Increased mortality after dronedarone therapy for severe heart failure, N Engl J Med, 358, 2678, 10.1056/NEJMoa0800456
Echt, 1991, Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial, N Engl J Med, 324, 781, 10.1056/NEJM199103213241201
Theuns, 2010, Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis, Europace, 12, 1564, 10.1093/europace/euq329
Elming, 2017, Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure, Circulation, 136, 1772, 10.1161/CIRCULATIONAHA.117.028829
Selvanayagam, 2017, Cardiovascular magnetic resonance-GUIDEd management of mild to moderate left ventricular systolic dysfunction (CMR GUIDE): Study protocol for a randomized controlled trial, Ann Noninvasive Electrocardiol, 22, e12420, 10.1111/anec.12420
Leyva, 2017, Outcomes of cardiac resynchronization therapy with or without defibrillation in patients with nonischemic cardiomyopathy, J Am Coll Cardiol, 70, 1216, 10.1016/j.jacc.2017.07.712
Di Marco, 2017, Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis, JACC Heart Fail, 5, 28, 10.1016/j.jchf.2016.09.017
Gulati, 2013, Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy, JAMA, 309, 896, 10.1001/jama.2013.1363
Stewart, 2010, Patient expectations from implantable defibrillators to prevent death in heart failure, J Card Fail, 16, 106, 10.1016/j.cardfail.2009.09.003
Moss, 2012, Reduction in inappropriate therapy and mortality through ICD programming, N Engl J Med, 367, 2275, 10.1056/NEJMoa1211107
Healey, 2015, IMPLant Evaluation Investigators. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE), Lancet, 385, 785, 10.1016/S0140-6736(14)61903-6
Gasparini, 2013, Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial, JAMA, 309, 1903, 10.1001/jama.2013.4598
Cleland, 2010, Device therapy: defibrillators--a shocking therapy for cardiomyopathy?, Nat Rev Cardiol, 7, 69, 10.1038/nrcardio.2009.233
Wilkoff, 2002, Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial, JAMA, 288, 3115, 10.1001/jama.288.24.3115
Boersma, 2017, Implant and midterm outcomes of the subcutaneous implantable cardioverter-defibrillator registry: the EFFORTLESS study, J Am Coll Cardiol, 70, 830, 10.1016/j.jacc.2017.06.040
Burke, 2015, Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS registry, J Am Coll Cardiol, 65, 1605, 10.1016/j.jacc.2015.02.047
Priori, 2015, 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), Eur Heart J, 36, 2793, 10.1093/eurheartj/ehv316
Knops, 2020, Subcutaneous or transvenous defibrillator therapy, N Engl J Med, 383, 526, 10.1056/NEJMoa1915932
Duncker, 2017, Avoiding untimely implantable cardioverter/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter/defibrillator--the PROLONG Study, J Am Heart Assoc, 6, e004512, 10.1161/JAHA.116.004512
Olgin, 2018, Wearable cardioverter-defibrillator after myocardial infarction, N Engl J Med, 379, 1205, 10.1056/NEJMoa1800781
Cazeau, 2001, Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay, N Engl J Med, 344, 873, 10.1056/NEJM200103223441202
Cleland, 2005, Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure, N Engl J Med, 352, 1539, 10.1056/NEJMoa050496
Daubert, 2009, Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial, J Am Coll Cardiol, 54, 1837, 10.1016/j.jacc.2009.08.011
Cleland, 2006, Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase], Eur Heart J, 27, 1928, 10.1093/eurheartj/ehl099
Cleland, 2012, Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial, Eur J Heart Fail, 14, 628, 10.1093/eurjhf/hfs055
Bristow, 2004, Comparison of Medical Therapy Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure, N Engl J Med, 350, 2140, 10.1056/NEJMoa032423
Cleland, 2013, An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure, Eur Heart J, 34, 3547, 10.1093/eurheartj/eht290
Tang, 2010, Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure, N Engl J Med, 363, 2385, 10.1056/NEJMoa1009540
Moss, 2009, Cardiac-resynchronization therapy for the prevention of heart-failure events, N Engl J Med, 361, 1329, 10.1056/NEJMoa0906431
Goldenberg, 2014, Survival with cardiac-resynchronization therapy in mild heart failure, N Engl J Med, 370, 1694, 10.1056/NEJMoa1401426
Linde, 2008, Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms, J Am Coll Cardiol, 52, 1834, 10.1016/j.jacc.2008.08.027
Curtis, 2013, Biventricular pacing for atrioventricular block and systolic dysfunction, N Engl J Med, 368, 1585, 10.1056/NEJMoa1210356
Brignole, 2011, Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial, Eur Heart J, 32, 2420, 10.1093/eurheartj/ehr162
Stavrakis, 2012, Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis, Europace, 14, 1490, 10.1093/europace/eus193
Leclercq, 2002, Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation, Eur Heart J, 23, 1780, 10.1053/euhj.2002.3232
Woods, 2015, Individual patient data network meta-analysis of mortality effects of implantable cardiac devices, Heart, 101, 1800, 10.1136/heartjnl-2015-307634
Gage, 2014, Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous right ventricular pacing, Eur J Heart Fail, 16, 1199, 10.1002/ejhf.143
Ruschitzka, 2013, Cardiac-resynchronization therapy in heart failure with a narrow QRS complex, N Engl J Med, 369, 1395, 10.1056/NEJMoa1306687
Steffel, 2015, The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial, Eur Heart J, 36, 1983, 10.1093/eurheartj/ehv242
Zusterzeel, 2014, Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data, JAMA Intern Med, 174, 1340, 10.1001/jamainternmed.2014.2717
Sohaib, 2015, Opportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ventricular pacing: evidence from randomized controlled trials, JACC Heart Fail, 3, 327, 10.1016/j.jchf.2014.11.007
Greenberg, 2004, Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II), J Am Coll Cardiol, 43, 1459, 10.1016/j.jacc.2003.11.038
Linde, 2013, Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study, Eur Heart J, 34, 2592, 10.1093/eurheartj/eht160
Cleland, 2015, Reflections on EchoCRT: sound guidance on QRS duration and morphology for CRT?, Eur Heart J, 36, 1948, 10.1093/eurheartj/ehv264
Linde, 2015, Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure, Europace, 17, 424, 10.1093/europace/euu205
Cunnington, 2015, Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials, Heart, 101, 1456, 10.1136/heartjnl-2014-306811
Doshi, 2005, Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study), J Cardiovasc Electrophysiol, 16, 1160, 10.1111/j.1540-8167.2005.50062.x
Koplan, 2009, Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure, of 100% biventricular pacing necessary? J Am Coll Cardiol, 53, 355, 10.1016/j.jacc.2008.09.043
Hawkins, 2009, Selecting patients for cardiac resynchronization therapy: the fallacy of echocardiographic dyssynchrony, J Am Coll Cardiol, 53, 1944, 10.1016/j.jacc.2008.11.062
Beela, 2019, Assessment of mechanical dyssynchrony can improve the prognostic value of guideline-based patient selection for cardiac resynchronization therapy, Eur Heart J Cardiovasc Imaging, 20, 66, 10.1093/ehjci/jey029
Khan, 2012, Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial, J Am Coll Cardiol, 59, 1509, 10.1016/j.jacc.2011.12.030
Saba, 2013, Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy: results of the Speckle Tracking Assisted Resynchronization Therapy for Electrode Region trial, Circ Heart Fail, 6, 427, 10.1161/CIRCHEARTFAILURE.112.000078
Kosmala, 2014, Meta-analysis of effects of optimization of cardiac resynchronization therapy on left ventricular function, exercise capacity, and quality of life in patients with heart failure, Am J Cardiol, 113, 988, 10.1016/j.amjcard.2013.12.006
Whinnett, 2013, Comparison of different invasive hemodynamic methods for AV delay optimization in patients with cardiac resynchronization therapy: implications for clinical trial design and clinical practice, Int J Cardiol, 168, 2228, 10.1016/j.ijcard.2013.01.216
Daubert, 2017, Avoiding non-responders to cardiac resynchronization therapy: a practical guide, Eur Heart J, 38, 1463
Mullens, 2020, Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology, Eur J Heart Fail, 22, 2349, 10.1002/ejhf.2046
Glikson M, Nielsen JC, Michowitz Y, Kronborg MB, Auricchio A, Barbash IM, Barrabés JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS, Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thylén I, Tolosana JM; ESC Scientific Document Group., 2021, 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy., Eur Heart J
Abraham, 2018, A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation, JACC Heart Fail, 6, 874, 10.1016/j.jchf.2018.04.010
NICE: National Institute for Health and Care Excellence, 28 2021
Abraham, 2015, Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction, JACC Heart Fail, 3, 487, 10.1016/j.jchf.2015.02.006
Zile, 2020, Baroreflex activation therapy in patients with heart failure with reduced ejection fraction, J Am Coll Cardiol, 76, 1, 10.1016/j.jacc.2020.05.015
Yusuf, 2003, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial, Lancet, 362, 777, 10.1016/S0140-6736(03)14285-7
Pitt, 2014, Spironolactone for heart failure with preserved ejection fraction, N Engl J Med, 370, 1383, 10.1056/NEJMoa1313731
Solomon, 2020, Sacubitril/valsartan across the spectrum of ejection fraction in heart failure, Circulation, 141, 352, 10.1161/CIRCULATIONAHA.119.044586
Rogers, 2014, Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved, Eur J Heart Fail, 16, 33, 10.1002/ejhf.29
van Veldhuisen, 2009, Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure), J Am Coll Cardiol, 53, 2150, 10.1016/j.jacc.2009.02.046
Hai, 2015, Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction, Eur J Heart Fail, 17, 135, 10.1002/ejhf.208
Shah, 2018, One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: a randomized clinical trial, JAMA Cardiol, 3, 968, 10.1001/jamacardio.2018.2936
Pfeffer, 2003, Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme, Lancet, 362, 759, 10.1016/S0140-6736(03)14282-1
Dewan, 2020, Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure, Eur J Heart Fail, 22, 898, 10.1002/ejhf.1776
Campbell, 2018, Redefining heart failure phenotypes based on ejection fraction, Eur J Heart Fail, 20, 1634, 10.1002/ejhf.1325
Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration, 2015, Ethnic-specific normative reference values for echocardiographic LA and LV size, LV mass, and systolic function: the EchoNoRMAL Study, JACC Cardiovasc Imaging, 8, 656, 10.1016/j.jcmg.2015.02.014
Wehner, 2020, Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?, Eur Heart J, 41, 1249, 10.1093/eurheartj/ehz550
Stewart, 2021, NEDA Investigators. Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men, Eur J Heart Fail, 23, 406, 10.1002/ejhf.2047
Borlaug, 2020, Evaluation and management of heart failure with preserved ejection fraction, Nat Rev Cardiol, 17, 559, 10.1038/s41569-020-0363-2
Pieske, 2019, How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), Eur Heart J, 40, 3297, 10.1093/eurheartj/ehz641
Ho, 2019, Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions, Circulation, 140, 353, 10.1161/CIRCULATIONAHA.118.039136
Reddy, 2018, A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction, Circulation, 138, 861, 10.1161/CIRCULATIONAHA.118.034646
Segar, 2019, Generalizability and implications of the H2FPEF score in a cohort of patients with heart failure with preserved ejection fraction, Circulation, 139, 1851, 10.1161/CIRCULATIONAHA.118.039051
Myhre, 2019, Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial, Eur J Heart Fail, 21, 1288, 10.1002/ejhf.1542
Sepehrvand, 2019, External validation of the H2F-PEF model in diagnosing patients with heart failure and preserved ejection fraction, Circulation, 139, 2377, 10.1161/CIRCULATIONAHA.118.038594
Sueta, 2019, H2FPEF score as a prognostic value in HFpEF patients, Am J Hypertens, 32, 1082, 10.1093/ajh/hpz108
Barandiaran Aizpurua, 2020, Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction, Eur J Heart Fail, 22, 413, 10.1002/ejhf.1614
Sanders-van Wijk, The HFA-PEFF and H2 FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction, Eur J Heart Fail, 23
Selvaraj, 2020, Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community, JACC Heart Fail, 8, 640, 10.1016/j.jchf.2020.03.013
Ouwerkerk, 2020, Heart failure with preserved ejection fraction diagnostic scores in an Asian population, Eur J Heart Fail, 22, 1737, 10.1002/ejhf.1851
Playford, 2021, Diastolic dysfunction and mortality in 436 360 men and women: the National Echo Database Australia (NEDA), Eur Heart J Cardiovasc Imaging, 22, 505, 10.1093/ehjci/jeaa253
Halliday, 2019, Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial, Lancet, 393, 61, 10.1016/S0140-6736(18)32484-X
Lupon, 2019, Bayes-Genis A. Heart failure with preserved ejection fraction infrequently evolves toward a reduced phenotype in long-term survivors, Circ Heart Fail, 12, e005652, 10.1161/CIRCHEARTFAILURE.118.005652
Savarese, 2019, Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure, JACC Heart Fail, 7, 306, 10.1016/j.jchf.2018.11.019
Nauta, 2018, Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction, Eur J Heart Fail, 20, 1303, 10.1002/ejhf.1220
Sharifov, 2016, Diagnostic accuracy of tissue Doppler index E/e' for evaluating left ventricular filling pressure and diastolic dysfunction/heart failure with preserved ejection fraction: a systematic review and meta-analysis, J Am Heart Assoc, 5, e002078, 10.1161/JAHA.115.002530
Eisman, 2018, Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure, Circ Heart Fail, 11, 10.1161/CIRCHEARTFAILURE.117.004750
Cleland, 1999, Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP Investigators, Eur J Heart Fail, 1, 211, 10.1016/S1388-9842(99)00039-2
Massie, 2008, Irbesartan in patients with heart failure and preserved ejection fraction, N Engl J Med, 359, 2456, 10.1056/NEJMoa0805450
Ahmed, 2006, Effects of digoxin on morbidity and mortality in diastolic heart failure: the Ancillary Digitalis Investigation Group trial, Circulation, 114, 397, 10.1161/CIRCULATIONAHA.106.628347
Redfield, 2015, Isosorbide mononitrate in heart failure with preserved ejection fraction, N Engl J Med, 373, 2314, 10.1056/NEJMoa1510774
Borlaug, 2018, Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial, JAMA, 320, 1764, 10.1001/jama.2018.14852
Armstrong, 2020, Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial, JAMA, 324, 1512, 10.1001/jama.2020.15922
Udelson, 2020, Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial, JAMA, 324, 1522, 10.1001/jama.2020.16641
Omar, 2018, The evolving role of cardiorespiratory fitness and exercise in prevention and management of heart failure, Curr Heart Fail Rep, 15, 75, 10.1007/s11897-018-0382-z
Kitzman, 2015, Hospitalizations and prognosis in elderly patients with heart failure and preserved ejection fraction: time to treat the whole patient, JACC Heart Fail, 3, 442, 10.1016/j.jchf.2015.01.009
Wood, 2018, Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies, Lancet, 391, 1513, 10.1016/S0140-6736(18)30134-X
Kostis, 1997, Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group, JAMA, 278, 212, 10.1001/jama.1997.03550030052033
Group, 2015, A randomized trial of intensive versus standard blood-pressure control, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939
Sciarretta, 2011, Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk, Arch Intern Med, 171, 384, 10.1001/archinternmed.2010.427
Beckett, 2008, Treatment of hypertension in patients 80 years of age or older, N Engl J Med, 358, 1887, 10.1056/NEJMoa0801369
Scirica, 2006, Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study, J Am Coll Cardiol, 47, 2326, 10.1016/j.jacc.2006.03.034
Kjekshus, 1997, The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease, J Card Fail, 3, 249, 10.1016/S1071-9164(97)90022-1
Zinman, 2015, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, 373, 2117, 10.1056/NEJMoa1504720
Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, 377, 644, 10.1056/NEJMoa1611925
Wiviott, 2019, DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes, N Engl J Med, 380, 347, 10.1056/NEJMoa1812389
Bhatt, 2020, Sotagliflozin in patients with diabetes and chronic kidney disease, N Engl J Med, 384, 129, 10.1056/NEJMoa2030186
Cannon, 2020, VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes, N Engl J Med, 383, 1425, 10.1056/NEJMoa2004967
Suskin, 2001, Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction, J Am Coll Cardiol, 37, 1677, 10.1016/S0735-1097(01)01195-0
Dorans, 2015, Alcohol and incident heart failure among middle-aged and elderly men: cohort of Swedish men, Circ Heart Fail, 8, 422, 10.1161/CIRCHEARTFAILURE.114.001787
Goncalves, 2015, Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study, Eur Heart J, 36, 939, 10.1093/eurheartj/ehu514
Pandey, 2015, Dose-response relationship between physical activity and risk of heart failure: a meta-analysis, Circulation, 132, 1786, 10.1161/CIRCULATIONAHA.115.015853
Padwal, 2014, Bayes-Genis A, Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data, Int J Obes (Lond, 38, 1110, 10.1038/ijo.2013.203
McDonagh, 2011, European Society of Cardiology Heart Failure Association Standards for delivering heart failure care, Eur J Heart Fail, 13, 235, 10.1093/eurjhf/hfq221
Lainscak, 2011, Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 13, 115, 10.1093/eurjhf/hfq219
Mebazaa, 2015, Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine--short version, Eur Heart J, 36, 1958, 10.1093/eurheartj/ehv066
McDonagh, 2014, Heart Failure Association of the European Society of Cardiology specialist heart failure curriculum, Eur J Heart Fail, 16, 151, 10.1002/ejhf.41
Riley, 2016, Heart Failure Association of the European Society of Cardiology heart failure nurse curriculum, Eur J Heart Fail, 18, 736, 10.1002/ejhf.568
Van Spall, 2017, Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis, Eur J Heart Fail, 19, 1427, 10.1002/ejhf.765
Jonkman, 2016, What are effective program characteristics of self-management interventions in patients with heart failure? An individual patient data meta-analysis, J Card Fail, 22, 861, 10.1016/j.cardfail.2016.06.422
Kalogirou, 2020, Heart failure disease management: a systematic review of effectiveness in heart failure with preserved ejection fraction, ESC Heart Fail, 7, 194
Hill, 2020, Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper, Eur J Heart Fail, 22, 2327, 10.1002/ejhf.1994
Kyriakou, 2020, Supportive care interventions to promote health-related quality of life in patients living with heart failure: a systematic review and meta-analysis, Heart Lung Circ, 29, 1633, 10.1016/j.hlc.2020.04.019
Feltner, 2014, Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis, Ann Intern Med, 160, 774, 10.7326/M14-0083
Blue, 2001, Randomised controlled trial of specialist nurse intervention in heart failure, BMJ, 323, 715, 10.1136/bmj.323.7315.715
Lambrinou, 2012, Effectiveness of heart failure management programmes with nurse-led discharge planning in reducing re-admissions: a systematic review and meta-analysis, Int J Nurs Stud, 49, 610, 10.1016/j.ijnurstu.2011.11.002
Stewart, 1999, Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure, Arch Intern Med, 159, 257, 10.1001/archinte.159.3.257
Ekman, 2012, Effects of person-centred care in patients with chronic heart failure: the PCC-HF study, Eur Heart J, 33, 1112, 10.1093/eurheartj/ehr306
Riegel, 2002, Cognitive impairment in heart failure: issues of measurement and etiology, Am J Crit Care, 11, 520, 10.4037/ajcc2002.11.6.520
Abraityte, 2019, T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF, Clin Res Cardiol, 108, 133, 10.1007/s00392-018-1331-2
Flynn, 2009, Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial, JAMA, 301, 1451, 10.1001/jama.2009.457
O'Connor, 2009, Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial, JAMA, 301, 1439, 10.1001/jama.2009.454
Taylor, 2019, Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis, J Am Coll Cardiol, 73, 1430, 10.1016/j.jacc.2018.12.072
Taylor, 2018, Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials, Eur J Heart Fail, 20, 1735, 10.1002/ejhf.1311
Pandey, 2015, Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials, Circ Heart Fail, 8, 33, 10.1161/CIRCHEARTFAILURE.114.001615
Taylor, 2019, Exercise-based rehabilitation for heart failure: Cochrane Systematic Review, meta-analysis, and trial sequential analysis, JACC Heart Fail, 7, 691, 10.1016/j.jchf.2019.04.023
Taylor, 2019, Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis, Health Technol Assess, 23, 1, 10.3310/hta23660
Cooper, 2015, Psychosocial factors, exercise adherence, and outcomes in heart failure patients: insights from Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION), Circ Heart Fail, 8, 1044, 10.1161/CIRCHEARTFAILURE.115.002327
Gomes Neto, 2018, High intensity interval training versus moderate intensity continuous training on exercise capacity and quality of life in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis, Int J Cardiol, 261, 134, 10.1016/j.ijcard.2018.02.076
Ellingsen, 2017, SMARTEX Heart Failure Study Group. High-intensity interval training in patients with heart failure with reduced ejection fraction, Circulation, 135, 839, 10.1161/CIRCULATIONAHA.116.022924
Edelmann, 2011, Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study, J Am Coll Cardiol, 58, 1780, 10.1016/j.jacc.2011.06.054
Nolte, 2015, Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial, Eur J Prev Cardiol, 22, 582, 10.1177/2047487314526071
Ismail, 2013, Clinical outcomes and cardiovascular responses to different exercise training intensities in patients with heart failure: a systematic review and meta-analysis, JACC Heart Fail, 1, 514, 10.1016/j.jchf.2013.08.006
Kitzman, 2013, Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial, J Am Coll Cardiol, 62, 584, 10.1016/j.jacc.2013.04.033
Ismail, 2013, Is exercise training beneficial for heart failure patients taking beta-adrenergic blockers? A systematic review and meta-analysis, Congest Heart Fail, 19, 61, 10.1111/chf.12000
Kitzman, 2016, Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial, JAMA, 315, 36, 10.1001/jama.2015.17346
Taylor, 2014, Exercise-based rehabilitation for heart failure, Cochrane Database Syst Rev
Schou, 2013, Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar), Eur Heart J, 34, 432, 10.1093/eurheartj/ehs235
Thorvaldsen, 2016, Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012, Eur J Heart Fail, 18, 503, 10.1002/ejhf.496
Lund, 2017, Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry, Eur J Heart Fail, 19, 1270, 10.1002/ejhf.781
Savarese, 2018, Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry, Eur J Heart Fail, 20, 1326, 10.1002/ejhf.1182
Lund, 2017, Association between enrolment in a heart failure quality registry and subsequent mortality--a nationwide cohort study, Eur J Heart Fail, 19, 1107, 10.1002/ejhf.762
Clark, 2008, The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure, Eur J Heart Fail, 10, 696, 10.1016/j.ejheart.2008.05.001
Troughton, 2000, Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations, Lancet, 355, 1126, 10.1016/S0140-6736(00)02060-2
Berger, 2010, N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study, J Am Coll Cardiol, 55, 645, 10.1016/j.jacc.2009.08.078
Jourdain, 2007, Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study, J Am Coll Cardiol, 49, 1733, 10.1016/j.jacc.2006.10.081
Lainchbury, 2009, N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial, J Am Coll Cardiol, 55, 53, 10.1016/j.jacc.2009.02.095
Pfisterer, 2009, BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial, JAMA, 301, 383, 10.1001/jama.2009.2
Felker, 2017, Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial, JAMA, 318, 713, 10.1001/jama.2017.10565
Porapakkham, 2010, B-type natriuretic peptide-guided heart failure therapy: a meta-analysis, Arch Intern Med, 170, 507, 10.1001/archinternmed.2010.35
Troughton, 2014, Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis, Eur Heart J, 35, 1559, 10.1093/eurheartj/ehu090
Anand, 2003, Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT), Circulation, 107, 1278, 10.1161/01.CIR.0000054164.99881.00
Zile, 2016, Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure, J Am Coll Cardiol, 68, 2425, 10.1016/j.jacc.2016.09.931
Brahmbhatt, 2019, Remote management of heart failure: an overview of telemonitoring technologies, Card Fail Rev, 5, 86, 10.15420/cfr.2019.5.3
Cleland, 2020, Caring for people with heart failure and many other medical problems through and beyond the COVID-19 pandemic: the advantages of universal access to home telemonitoring, Eur J Heart Fail, 22, 995, 10.1002/ejhf.1864
Inglis, 2017, Structured telephone support or non-invasive telemonitoring for patients with heart failure, Heart, 103, 255, 10.1136/heartjnl-2015-309191
Frederix, 2019, ESC e-Cardiology Working Group Position Paper: Overcoming challenges in digital health implementation in cardiovascular medicine, Eur J Prev Cardiol, 26, 1166, 10.1177/2047487319832394
Lin, 2017, Clinical effectiveness of telemedicine for chronic heart failure: a systematic review and meta-analysis, J Investig Med, 65, 899, 10.1136/jim-2016-000199
Adamson, 2017, Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials, Eur J Heart Fail, 19, 426, 10.1002/ejhf.638
Chaudhry, 2010, Telemonitoring in patients with heart failure, N Engl J Med, 363, 2301, 10.1056/NEJMoa1010029
Koehler, 2011, Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study, Circulation, 123, 1873, 10.1161/CIRCULATIONAHA.111.018473
Koehler, 2018, Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the intervention, Eur J Heart Fail, 20, 1485, 10.1002/ejhf.1300
Koehler, 2018, Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial, Lancet, 392, 1047, 10.1016/S0140-6736(18)31880-4
Kalter-Leibovici, 2017, Israel Heart Failure Disease Management Study investigators. Disease management in the treatment of patients with chronic heart failure who have universal access to health care: a randomized controlled trial, BMC Med, 15, 90, 10.1186/s12916-017-0855-z
Jayaram, 2017, Impact of telemonitoring on health status, Circ Cardiovasc Qual Outcomes, 10, 10.1161/CIRCOUTCOMES.117.004148
Shochat, 2016, Non-invasive lung IMPEDANCE-guided preemptive treatment in chronic heart failure patients: a randomized controlled trial (IMPEDANCE-HF Trial), J Card Fail, 22, 713, 10.1016/j.cardfail.2016.03.015
van Veldhuisen, 2011, Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure, Circulation, 124, 1719, 10.1161/CIRCULATIONAHA.111.043042
Hindricks, 2014, Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial, Lancet, 384, 583, 10.1016/S0140-6736(14)61176-4
Morgan, 2017, Remote management of heart failure using implantable electronic devices, Eur Heart J, 38, 2352, 10.1093/eurheartj/ehx227
Bohm, 2016, Fluid status telemedicine alerts for heart failure: a randomized controlled trial, Eur Heart J, 37, 3154, 10.1093/eurheartj/ehw099
Abraham, 2016, CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial, Lancet, 387, 453, 10.1016/S0140-6736(15)00723-0
Lindenfeld, 2019, Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF), Am Heart J, 214, 18, 10.1016/j.ahj.2019.04.014
Dierckx, 2017, Telemedicine in heart failure: new insights from the Cochrane meta-analyses, Eur J Heart Fail, 19, 304, 10.1002/ejhf.759
Fang, 2015, Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee, J Card Fail, 21, 519, 10.1016/j.cardfail.2015.04.013
Crespo-Leiro, 2018, Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 20, 1505, 10.1002/ejhf.1236
Truby, 2020, Advanced heart failure: epidemiology, diagnosis, and therapeutic approaches, JACC Heart Fail, 8, 523, 10.1016/j.jchf.2020.01.014
Rose, 2001, Long-term use of a left ventricular assist device for end-stage heart failure, N Engl J Med, 345, 1435, 10.1056/NEJMoa012175
Ammar, 2007, Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community, Circulation, 115, 1563, 10.1161/CIRCULATIONAHA.106.666818
Xanthakis, 2016, Prevalence, neurohormonal correlates, and prognosis of heart failure stages in the community, JACC Heart Fail, 4, 808, 10.1016/j.jchf.2016.05.001
Stevenson, 2009, INTERMACS profiles of advanced heart failure: the current picture, J Heart Lung Transplant, 28, 535, 10.1016/j.healun.2009.02.015
Barge-Caballero, 2013, Preoperative INTERMACS profiles determine postoperative outcomes in critically ill patients undergoing emergency heart transplantation: analysis of the Spanish National Heart Transplant Registry, Circ Heart Fail, 6, 763, 10.1161/CIRCHEARTFAILURE.112.000237
Goldstein, 2019, Third annual report from the ISHLT Mechanically Assisted Circulatory Support Registry: a comparison of centrifugal and axial continuous-flow left ventricular assist devices, J Heart Lung Transplant, 38, 352, 10.1016/j.healun.2019.02.004
Kittleson, 2020, INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: a report from the REVIVAL Registry, J Heart Lung Transplant, 39, 16, 10.1016/j.healun.2019.08.017
Mehra, 2016, The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update, J Heart Lung Transplant, 35, 1, 10.1016/j.healun.2015.10.023
Baumwol, 2017, "I need help"--a mnemonic to aid timely referral in advanced heart failure, J Heart Lung Transplant, 36, 593, 10.1016/j.healun.2017.02.010
Ahmad, 2019, Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials, Eur J Heart Fail, 21, 1064, 10.1002/ejhf.1557
Comin-Colet, 2018, Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial, Eur J Heart Fail, 20, 1128, 10.1002/ejhf.1145
Nizamic, 2018, Ambulatory inotrope infusions in advanced heart failure: a systematic review and meta-analysis, JACC Heart Fail, 6, 757, 10.1016/j.jchf.2018.03.019
Bart, 2012, Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome, N Engl J Med, 367, 2296, 10.1056/NEJMoa1210357
Costanzo, 2007, UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure, J Am Coll Cardiol, 49, 675, 10.1016/j.jacc.2006.07.073
Gustafsson, 2017, Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes, Eur J Heart Fail, 19, 595, 10.1002/ejhf.779
Barge-Caballero, 2018, Clinical outcomes of temporary mechanical circulatory support as a direct bridge to heart transplantation: a nationwide Spanish registry, Eur J Heart Fail, 20, 178, 10.1002/ejhf.956
Potapov, 2019, 2019 EACTS Expert Consensus on long-term mechanical circulatory support, Eur J Cardiothorac Surg, 56, 230, 10.1093/ejcts/ezz098
Rogers, 2007, Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial, J Am Coll Cardiol, 50, 741, 10.1016/j.jacc.2007.03.063
Slaughter, 2009, Advanced heart failure treated with continuous-flow left ventricular assist device, N Engl J Med, 361, 2241, 10.1056/NEJMoa0909938
Starling, 2011, Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support), J Am Coll Cardiol, 57, 1890, 10.1016/j.jacc.2010.10.062
Rogers, 2017, Intrapericardial left ventricular assist device for advanced heart failure, N Engl J Med, 376, 451, 10.1056/NEJMoa1602954
Truby, 2019, Impact of bridge to transplantation with continuous-flow left ventricular assist devices on posttransplantation mortality, Circulation, 140, 459, 10.1161/CIRCULATIONAHA.118.036932
Goldstein, 2020, Association of clinical outcomes with left ventricular assist device use by bridge to transplant or destination therapy intent: the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial, JAMA Cardiol, 5, 411, 10.1001/jamacardio.2019.5323
Mehra, 2019, A fully magnetically levitated left ventricular assist device -- final report, N Engl J Med, 380, 1618, 10.1056/NEJMoa1900486
Kirklin, 2015, Seventh INTERMACS annual report: 15,000 patients and counting, J Heart Lung Transplant, 34, 1495, 10.1016/j.healun.2015.10.003
Theochari, 2018, Heart transplantation versus left ventricular assist devices as destination therapy or bridge to transplantation for 1-year mortality: a systematic review and meta-analysis, Ann Cardiothorac Surg, 7, 3, 10.21037/acs.2017.09.18
Mehra, 2018, Two-year outcomes with a magnetically levitated cardiac pump in heart failure, N Engl J Med, 378, 1386, 10.1056/NEJMoa1800866
Zimpfer, 2020, Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry, Eur Heart J, 41, 3801, 10.1093/eurheartj/ehaa639
Estep, 2015, Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study, J Am Coll Cardiol, 66, 1747, 10.1016/j.jacc.2015.07.075
Starling, 2017, Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP study 2-year results, JACC Heart Fail, 5, 518, 10.1016/j.jchf.2017.02.016
Slaughter, 2013, HeartWare Bridge to Transplant ADVANCE Trial Investigators. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial, J Heart Lung Transplant, 32, 675, 10.1016/j.healun.2013.04.004
Karason, 2020, Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial, Eur J Heart Fail, 22, 739, 10.1002/ejhf.1773
Khush, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report--2019; focus theme: donor and recipient size match, J Heart Lung Transplant, 38, 1056, 10.1016/j.healun.2019.08.004
Lund, 2013, The Registry of the International Society for Heart and Lung Transplantation: Thirtieth official adult heart transplant report--2013; focus theme: age, J Heart Lung Transplant, 32, 951, 10.1016/j.healun.2013.08.006
Guglin, 2020, Evaluation for heart transplantation and LVAD implantation: JACC Council perspectives, J Am Coll Cardiol, 75, 1471, 10.1016/j.jacc.2020.01.034
Bernhardt, 2020, Driveline Expert STagINg and carE DESTINE study group, a Ventricular Assist Device Driveline Infection Study Group. Prevention and early treatment of driveline infections in ventricular assist device patients -- the DESTINE staging proposal and the first standard of care protocol, J Crit Care, 56, 106, 10.1016/j.jcrc.2019.12.014
DeFilippis, 2020, Psychosocial risk and its association with outcomes in continuous-flow left ventricular assist device patients, Circ Heart Fail, 13, e006910, 10.1161/CIRCHEARTFAILURE.120.006910
Jaarsma, 2021, Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 23, 157, 10.1002/ejhf.2008
Jorde, 2014, Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support), J Am Coll Cardiol, 63, 1751, 10.1016/j.jacc.2014.01.053
Sahlollbey, 2020, The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials, Eur J Heart Fail, 22, 2340, 10.1002/ejhf.1783
Fendler, 2015, Team-based palliative and end-of-life care for heart failure, Heart Fail Clin, 11, 479, 10.1016/j.hfc.2015.03.010
Brannstrom, 2014, Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study, Eur J Heart Fail, 16, 1142, 10.1002/ejhf.151
O'Donnell, 2018, Social worker-aided palliative care intervention in high-risk patients with Heart Failure (SWAP-HF): a pilot randomized clinical trial, JAMA Cardiol, 3, 516, 10.1001/jamacardio.2018.0589
Johnson, 2002, Morphine for the relief of breathlessness in patients with chronic heart failure--a pilot study, Eur J Heart Fail, 4, 753, 10.1016/S1388-9842(02)00158-7
Oxberry, 2013, Repeat dose opioids may be effective for breathlessness in chronic heart failure if given for long enough, J Palliat Med, 16, 250, 10.1089/jpm.2012.0270
Blinderman, 2015, Comfort care for patients dying in the hospital, N Engl J Med, 373, 2549, 10.1056/NEJMra1411746
Nieminen, 2006, EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population, Eur Heart J, 27, 2725, 10.1093/eurheartj/ehl193
Chioncel, 2017, Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry, Eur J Heart Fail, 19, 1242, 10.1002/ejhf.890
Chioncel, 2019, Acute heart failure congestion and perfusion status -- impact of the clinical classification on in-hospital and long-term outcomes: insights from the ESC-EORP-HFA heart failure long-term registry, Eur J Heart Fail, 21, 1338, 10.1002/ejhf.1492
Miro, 2019, Departments involved during the first episode of acute heart failure and subsequent emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort, Eur J Heart Fail, 21, 1231, 10.1002/ejhf.1567
Solomon, 2007, Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure, Circulation, 116, 1482, 10.1161/CIRCULATIONAHA.107.696906
Tomasoni, 2020, Acute heart failure: more questions than answers, Prog Cardiovasc Dis, 63, 599, 10.1016/j.pcad.2020.04.007
Butt, 2020, Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort, Eur J Heart Fail, 22, 1777, 10.1002/ejhf.1800
Javaloyes, 2019, Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes, Eur J Heart Fail, 21, 1353, 10.1002/ejhf.1502
Januzzi, 2006, NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study, Eur Heart J, 27, 330, 10.1093/eurheartj/ehi631
Januzzi, 2018, Gaggin HK, ICON-RELOADED Investigators. N-terminal pro-B-type natriuretic peptide in the emergency department: the ICON-RELOADED study, J Am Coll Cardiol, 71, 1191, 10.1016/j.jacc.2018.01.021
Maisel, 2010, Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial, J Am Coll Cardiol, 55, 2062, 10.1016/j.jacc.2010.02.025
Harjola, 2020, Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 22, 1298, 10.1002/ejhf.1831
Harjola, 2017, Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), Eur J Heart Fail, 19, 821, 10.1002/ejhf.872
Harjola, 2018, Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), Eur J Heart Fail, 20, 1081, 10.1002/ejhf.1204
Ter Maaten, 2016, Hypochloremia, diuretic resistance, and outcome in patients with acute heart failure, Circ Heart Fail, 9, 10.1161/CIRCHEARTFAILURE.116.003109
Nunez, 2020, Bayes-Genis A. CA125-guided diuretic treatment versus usual care in patients with acute heart failure and renal dysfunction, Am J Med, 133, 370, 10.1016/j.amjmed.2019.07.041
Nikolaou, 2013, Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure, Eur Heart J, 34, 742, 10.1093/eurheartj/ehs332
Mockel, 2020, Improve Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18, Eur J Heart Fail, 22, 267, 10.1002/ejhf.1667
Masip, 2012, Peripheral venous blood gases and pulse-oximetry in acute cardiogenic pulmonary oedema, Eur Heart J Acute Cardiovasc Care, 1, 275, 10.1177/2048872612457087
Masip, 2012, Pulse oximetry in the diagnosis of acute heart failure, Rev Esp Cardiol (Engl Ed), 65, 879, 10.1016/j.recesp.2012.02.022
Nieminen, 2005, Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology, Eur Heart J, 26, 384, 10.1093/eurheartj/ehi044
Nohria, 2003, Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure, J Am Coll Cardiol, 41, 1797, 10.1016/S0735-1097(03)00309-7
Gheorghiade, 2010, European Society of Cardiology, European Society of Intensive Care Medicine. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine, Eur J Heart Fail, 12, 423, 10.1093/eurjhf/hfq045
Masip, 2018, Indications and practical approach to non-invasive ventilation in acute heart failure, Eur Heart J, 39, 17, 10.1093/eurheartj/ehx580
Harjola, 2016, Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology, Eur J Heart Fail, 18, 226, 10.1002/ejhf.478
Chioncel, 2020, Epidemiology, pathophysiology and contemporary management of cardiogenic shock -- a position statement from the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 22, 1315, 10.1002/ejhf.1922
Thiele, 2019, Management of cardiogenic shock complicating myocardial infarction: an update 2019, Eur Heart J, 40, 2671, 10.1093/eurheartj/ehz363
Mebazaa, 2018, Management of cardiogenic shock complicating myocardial infarction, Intensive Care Med, 44, 760, 10.1007/s00134-018-5214-9
Zymlinski, 2018, Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion, Eur J Heart Fail, 20, 1011, 10.1002/ejhf.1156
Menon, 2000, Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry, Am J Med, 108, 374, 10.1016/S0002-9343(00)00310-7
Harjola, 2020, Pre-hospital management protocols and perceived difficulty in diagnosing acute heart failure, ESC Heart Fail, 7, 289
Takahashi, 2011, Association between prehospital time interval and short-term outcome in acute heart failure patients, J Card Fail, 17, 742, 10.1016/j.cardfail.2011.05.005
Park, 2010, Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction, Heart, 96, 533, 10.1136/hrt.2009.175257
Gray, 2008, 3CPO Trialists Noninvasive ventilation in acute cardiogenic pulmonary edema, N Engl J Med, 359, 142, 10.1056/NEJMoa0707992
Weng, 2010, Meta-analysis: noninvasive ventilation in acute cardiogenic pulmonary edema, Ann Intern Med, 152, 590, 10.7326/0003-4819-152-9-201005040-00009
Felker, 2011, Diuretic strategies in patients with acute decompensated heart failure, N Engl J Med, 364, 797, 10.1056/NEJMoa1005419
Felker, 2020, Diuretic therapy for patients with heart failure: JACC state-of-the-art review, J Am Coll Cardiol, 75, 1178, 10.1016/j.jacc.2019.12.059
Brisco, 2016, Relevance of changes in serum creatinine during a heart failure trial of decongestive strategies: insights from the DOSE trial, J Card Fail, 22, 753, 10.1016/j.cardfail.2016.06.423
Damman, 2016, Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction, Eur J Heart Fail, 18, 328, 10.1002/ejhf.462
Ter Maaten, 2020, Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction, Clin Res Cardiol, 109, 1048, 10.1007/s00392-020-01598-w
Cubbon, 2014, Prospective development and validation of a model to predict heart failure hospitalisation, Heart, 100, 923, 10.1136/heartjnl-2013-305294
Kapelios, 2020, Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP heart failure long-term registry, Eur J Heart Fail, 22, 1424, 10.1002/ejhf.1796
Mebazaa, 2015, Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine, Eur J Heart Fail, 17, 544, 10.1002/ejhf.289
Damman, 2020, Clinical importance of urinary sodium excretion in acute heart failure, Eur J Heart Fail, 22, 1438, 10.1002/ejhf.1753
Mullens, 2018, Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial, Eur J Heart Fail, 20, 1591, 10.1002/ejhf.1307
Cox, 2020, Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial, JACC Heart Fail, 8, 157, 10.1016/j.jchf.2019.09.012
Damman, 2015, The kidney in heart failure: an update, Eur Heart J, 36, 1437, 10.1093/eurheartj/ehv010
Ambrosy, 2013, EVEREST Trial Investigators. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial, Eur Heart J, 34, 835, 10.1093/eurheartj/ehs444
Faselis, 2020, Loop diuretic prescription and 30-day outcomes in older patients with heart failure, J Am Coll Cardiol, 76, 669, 10.1016/j.jacc.2020.06.022
Sharon, 2000, High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema, J Am Coll Cardiol, 36, 832, 10.1016/S0735-1097(00)00785-3
2002, Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial, JAMA, 287, 1531
Cotter, 1998, Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema, Lancet, 351, 389, 10.1016/S0140-6736(97)08417-1
Levy, 2007, Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis, Ann Emerg Med, 50, 144, 10.1016/j.annemergmed.2007.02.022
Mebazaa, 2018, ESC Heart Failure Long-Term Registry Investigators. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology heart failure long-term registry, Eur J Heart Fail, 20, 332, 10.1002/ejhf.991
Kozhuharov, 2019, Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial, JAMA, 322, 2292, 10.1001/jama.2019.18598
Freund, 2020, Effect of an emergency department care bundle on 30-day hospital discharge and survival among elderly patients with acute heart failure: the ELISABETH randomized clinical trial, JAMA, 324, 1948, 10.1001/jama.2020.19378
Khot, 2003, Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis, N Engl J Med, 348, 1756, 10.1056/NEJMoa022021
Mebazaa, 2009, Cohen-Solal A. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE, Eur J Heart Fail, 11, 304, 10.1093/eurjhf/hfn045
Metra, 2002, Dei Cas L. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol, J Am Coll Cardiol, 40, 1248, 10.1016/S0735-1097(02)02134-4
Packer, 2013, Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure, JACC Heart Fail, 1, 103, 10.1016/j.jchf.2012.12.004
De Backer, 2010, SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock, N Engl J Med, 362, 779, 10.1056/NEJMoa0907118
Levy, 2018, Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction, J Am Coll Cardiol, 72, 173, 10.1016/j.jacc.2018.04.051
Leopold, 2018, Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients, Intensive Care Med, 44, 847, 10.1007/s00134-018-5222-9
Peacock, 2008, Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis, Emerg Med J, 25, 205, 10.1136/emj.2007.050419
Gil, 2019, Morphine use in the treatment of acute cardiogenic pulmonary edema and its effects on patient outcome: a systematic review, Curr Heart Fail Rep, 16, 81, 10.1007/s11897-019-00427-0
Miro, 2017, Morphine use in the ED and outcomes of patients with acute heart failure: a propensity score-matching analysis based on the EAHFE registry, Chest, 152, 821, 10.1016/j.chest.2017.03.037
Caspi, 2019, Adverse dose-dependent effects of morphine therapy in acute heart failure, Int J Cardiol, 293, 131, 10.1016/j.ijcard.2019.06.015
Sethi, 2018, Digoxin for atrial fibrillation and atrial flutter: a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials, PLoS One, 13, e0193924, 10.1371/journal.pone.0193924
Khand, 2003, Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?, J Am Coll Cardiol, 42, 1944, 10.1016/j.jacc.2003.07.020
Tebbe, 2011, Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study, Am Heart J, 161, 322, 10.1016/j.ahj.2010.10.005
Dentali, 2007, Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients, Ann Intern Med, 146, 278, 10.7326/0003-4819-146-4-200702200-00007
Seferovic, 2020, Heart Failure Association Board of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology quality of care centres programme: design and accreditation document, Eur J Heart Fail, 22, 763, 10.1002/ejhf.1784
Tehrani, 2019, Standardized team-based care for cardiogenic shock, J Am Coll Cardiol, 73, 1659, 10.1016/j.jacc.2018.12.084
Basir, 2019, National Cardiogenic Shock Initiative Investigators. Improved outcomes associated with the use of shock protocols: updates from the National Cardiogenic Shock Initiative, Catheter Cardiovasc Interv, 93, 1173, 10.1002/ccd.28307
Tehrani, 2020, A standardized and comprehensive approach to the management of cardiogenic shock, JACC Heart Fail, 8, 879, 10.1016/j.jchf.2020.09.005
Thiele, 2012, Intraaortic balloon support for myocardial infarction with cardiogenic shock, N Engl J Med, 367, 1287, 10.1056/NEJMoa1208410
Thiele, 2013, Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial, Lancet, 382, 1638, 10.1016/S0140-6736(13)61783-3
Thiele, 2019, Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABP-SHOCK II Trial, Circulation, 139, 395, 10.1161/CIRCULATIONAHA.118.038201
Seyfarth, 2008, A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction, J Am Coll Cardiol, 52, 1584, 10.1016/j.jacc.2008.05.065
Ouweneel, 2017, Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction, J Am Coll Cardiol, 69, 278, 10.1016/j.jacc.2016.10.022
Schrage, 2019, Impella support for acute myocardial infarction complicated by cardiogenic shock, Circulation, 139, 1249, 10.1161/CIRCULATIONAHA.118.036614
Dhruva, 2020, Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock, JAMA, 323, 734, 10.1001/jama.2020.0254
Kar, 2011, The percutaneous ventricular assist device in severe refractory cardiogenic shock, J Am Coll Cardiol, 57, 688, 10.1016/j.jacc.2010.08.613
Ouweneel, 2016, Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis, Intensive Care Med, 42, 1922, 10.1007/s00134-016-4536-8
Combes, 2020, Temporary circulatory support for cardiogenic shock, Lancet, 396, 199, 10.1016/S0140-6736(20)31047-3
Pappalardo, 2017, Concomitant implantation of Impella((R)) on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock, Eur J Heart Fail, 19, 404, 10.1002/ejhf.668
Anderson, 2015, Benefits of a novel percutaneous ventricular assist device for right heart failure: the prospective RECOVER RIGHT study of the Impella RP device, J Heart Lung Transplant, 34, 1549, 10.1016/j.healun.2015.08.018
Ponikowski, 2020, Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial, Lancet, 396, 1895, 10.1016/S0140-6736(20)32339-4
Bhagat, 2019, Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization, JACC Heart Fail, 7, 1, 10.1016/j.jchf.2018.06.011
Prins, 2015, Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis, JACC Heart Fail, 3, 647, 10.1016/j.jchf.2015.03.008
Metra, 2010, Postdischarge assessment after a heart failure hospitalization: the next step forward, Circulation, 122, 1782, 10.1161/CIRCULATIONAHA.110.982207
Greene, 2015, The vulnerable phase after hospitalization for heart failure, Nat Rev Cardiol, 12, 220, 10.1038/nrcardio.2015.14
Lee, 2016, Post-discharge Follow-up characteristics associated with 30-day readmission after heart failure hospitalization, Med Care, 54, 365, 10.1097/MLR.0000000000000492
Edmonston, 2019, Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients, Am Heart J, 212, 101, 10.1016/j.ahj.2019.03.005
Ling, 2016, Comorbidity of atrial fibrillation and heart failure, Nat Rev Cardiol, 13, 131, 10.1038/nrcardio.2015.191
Carlisle, 2019, Heart failure and atrial fibrillation, like fire and fury, JACC Heart Fail, 7, 447, 10.1016/j.jchf.2019.03.005
Gorenek, 2020, Atrial fibrillation in acute heart failure: a position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology, Eur Heart J Acute Cardiovasc Care, 9, 348, 10.1177/2048872619894255
Slawik, 2019, Irregular pacing of ventricular cardiomyocytes induces pro-fibrotic signalling involving paracrine effects of transforming growth factor beta and connective tissue growth factor, Eur J Heart Fail, 21, 482, 10.1002/ejhf.1392
Kotecha, 2016, Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins, J Am Coll Cardiol, 68, 2217, 10.1016/j.jacc.2016.08.048
Smit, 2012, The importance of whether atrial fibrillation or heart failure develops first, Eur J Heart Fail, 14, 1030, 10.1093/eurjhf/hfs097
Swedberg, 2005, Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET, Eur Heart J, 26, 1303, 10.1093/eurheartj/ehi166
Mogensen, 2017, PARADIGM-HF and ATMOSPHERE Investigators and Committees. Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction, J Am Coll Cardiol, 70, 2490, 10.1016/j.jacc.2017.09.027
Hoppe, 2006, Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure, Circulation, 114, 18, 10.1161/CIRCULATIONAHA.106.614560
Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0
Reddy, 2013, Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial, Circulation, 127, 720, 10.1161/CIRCULATIONAHA.112.114389
Holmes, 2014, Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial, J Am Coll Cardiol, 64, 1, 10.1016/j.jacc.2014.04.029
Van Gelder, 2006, RACE and AFFIRM Investigators. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies, Europace, 8, 935, 10.1093/europace/eul106
Hess, 2020, Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the Get With The Guidelines -- Heart Failure Program), Am J Cardiol, 125, 894, 10.1016/j.amjcard.2019.12.025
Sartipy, 2019, Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction, Eur J Heart Fail, 21, 471, 10.1002/ejhf.1389
Van Gelder, 2016, Rate control in atrial fibrillation, Lancet, 388, 818, 10.1016/S0140-6736(16)31258-2
Kotecha, 2017, Beta-Blockers in Heart Failure Collaborative Group. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure, J Am Coll Cardiol, 69, 2885, 10.1016/j.jacc.2017.04.001
Kotecha, 2020, Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial, JAMA, 324, 2497, 10.1001/jama.2020.23138
Hofmann, 2006, Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate, Int J Cardiol, 110, 27, 10.1016/j.ijcard.2005.06.048
Wood, 2000, Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis, Circulation, 101, 1138, 10.1161/01.CIR.101.10.1138
Lim, 2007, Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial, Europace, 9, 498, 10.1093/europace/eum091
Gasparini, 2018, Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations, Eur J Heart Fail, 20, 1472, 10.1002/ejhf.1117
Deedwania, 1998, Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators, Circulation, 98, 2574, 10.1161/01.CIR.98.23.2574
Antiarrhythmic Drug Evaluation Group (A.D.E, 1992, A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias, Eur Heart J, 13, 1251, 10.1093/oxfordjournals.eurheartj.a060345
Connolly, 2011, Dronedarone in high-risk permanent atrial fibrillation, N Engl J Med, 365, 2268, 10.1056/NEJMoa1109867
Chatterjee, 2012, Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure, Am J Cardiol, 110, 607, 10.1016/j.amjcard.2012.04.034
Shelton, 2009, A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study), Heart, 95, 924, 10.1136/hrt.2008.158931
Capucci, 2000, Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation, Eur Heart J, 21, 66, 10.1053/euhj.1999.1734
Van Gelder, 2002, A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation, N Engl J Med, 347, 1834, 10.1056/NEJMoa021375
Wyse, 2002, Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation, N Engl J Med, 347, 1825, 10.1056/NEJMoa021328
Carlsson, 2003, Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study, J Am Coll Cardiol, 41, 1690, 10.1016/S0735-1097(03)00332-2
Roy, 2008, Rhythm control versus rate control for atrial fibrillation and heart failure, N Engl J Med, 358, 2667, 10.1056/NEJMoa0708789
Kirchhof, 2020, EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation, N Engl J Med, 383, 1305, 10.1056/NEJMoa2019422
Marrouche, 2018, Catheter ablation for atrial fibrillation with heart failure, N Engl J Med, 378, 417, 10.1056/NEJMoa1707855
Packer, 2019, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1261, 10.1001/jama.2019.0693
Packer, 2021, Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial, Circulation, 143, 1377, 10.1161/CIRCULATIONAHA.120.050991
Kuck, 2019, Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial, Circ Arrhythm Electrophysiol, 12, e007731, 10.1161/CIRCEP.119.007731
Di Biase, 2016, Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial, Circulation, 133, 1637, 10.1161/CIRCULATIONAHA.115.019406
Mark, 2019, Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1275, 10.1001/jama.2019.0692
Xiong, 2015, Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials, Eur J Heart Fail, 17, 1192, 10.1002/ejhf.343
Nielsen, 2016, Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study, Sci Rep, 6, 27410, 10.1038/srep27410
Latchamsetty, 2019, Premature ventricular complex-induced cardiomyopathy, JACC Clin Electrophysiol, 5, 537, 10.1016/j.jacep.2019.03.013
Mondesert, 2016, Impact of revascularization in patients with sustained ventricular arrhythmias, prior myocardial infarction, and preserved left ventricular ejection fraction, Heart Rhythm, 13, 1221, 10.1016/j.hrthm.2016.01.019
Yarlagadda, 2005, Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract, Circulation, 112, 1092, 10.1161/CIRCULATIONAHA.105.546432
Berruezo, 2019, Mortality and morbidity reduction after frequent premature ventricular complexes ablation in patients with left ventricular systolic dysfunction, Europace, 21, 1079, 10.1093/europace/euz027
Cronin, 2019, HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias, Europace, 21, 1143, 10.1093/europace/euz132
Cho, 2019, Clinical features, predictors, and long-term prognosis of pacing-induced cardiomyopathy, Eur J Heart Fail, 21, 643, 10.1002/ejhf.1427
Vijayaraman, 2019, His-optimized cardiac resynchronization therapy to maximize electrical resynchronization: a feasibility study, Circ Arrhythm Electrophysiol, 12, e006934, 10.1161/CIRCEP.118.006934
Abdelrahman, 2018, Clinical outcomes of His bundle pacing compared to right ventricular pacing, J Am Coll Cardiol, 71, 2319, 10.1016/j.jacc.2018.02.048
Ziff, 2020, Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment, BMC Med, 18, 103, 10.1186/s12916-020-01564-3
Fox, 2009, Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial, Eur Heart J, 30, 2337, 10.1093/eurheartj/ehp358
Packer, 1996, Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group, N Engl J Med, 335, 1107, 10.1056/NEJM199610103351504
Cohn, 1997, Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group, Circulation, 96, 856, 10.1161/01.CIR.96.3.856
IONA Study Group, 2002, Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial, Lancet, 359, 1269, 10.1016/S0140-6736(02)08265-X
Kanamasa, 2002, Long-term, continuous treatment with both oral and transdermal nitrates increases cardiac events in healed myocardial infarction patients, Angiology, 53, 399, 10.1177/000331970205300405
Wilson, 2009, Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial, J Am Coll Cardiol, 53, 1510, 10.1016/j.jacc.2009.01.037
Gao, 2011, Trimetazidine: a meta-analysis of randomised controlled trials in heart failure, Heart, 97, 278, 10.1136/hrt.2010.208751
Vitale, 2004, Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease, Eur Heart J, 25, 1814, 10.1016/j.ehj.2004.06.034
Zhang, 2012, Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis, J Am Coll Cardiol, 59, 913, 10.1016/j.jacc.2011.11.027
Goldstein, 1991, Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group, Circulation, 83, 52, 10.1161/01.CIR.83.1.52
Zannad, 2018, Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease, N Engl J Med, 379, 1332, 10.1056/NEJMoa1808848
Branch, 2019, Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease, Circulation, 140, 529, 10.1161/CIRCULATIONAHA.119.039609
Velazquez, 2016, Coronary-artery bypass surgery in patients with ischemic cardiomyopathy, N Engl J Med, 374, 1511, 10.1056/NEJMoa1602001
Panza, 2013, Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction, J Am Coll Cardiol, 61, 1860, 10.1016/j.jacc.2013.02.014
Cleland, 2011, The Heart Failure Revascularisation Trial (HEART), Eur J Heart Fail, 13, 227, 10.1093/eurjhf/hfq230
Perera, 2018, Percutaneous revascularization for ischemic ventricular dysfunction: rationale and design of the REVIVED-BCIS2 trial: percutaneous coronary intervention for ischemic cardiomyopathy, JACC Heart Fail, 6, 517, 10.1016/j.jchf.2018.01.024
Bangalore, 2016, Revascularization in patients with multivessel coronary artery disease and severe left ventricular systolic dysfunction: everolimus-eluting stents versus coronary artery bypass graft surgery, Circulation, 133, 2132, 10.1161/CIRCULATIONAHA.115.021168
Nagendran, 2018, Coronary artery bypass surgery improves outcomes in patients with diabetes and left ventricular dysfunction, J Am Coll Cardiol, 71, 819, 10.1016/j.jacc.2017.12.024
Park, 2020, IRIS-MAIN Registry Investigators. Revascularization in patients with left main coronary artery disease and left ventricular dysfunction, J Am Coll Cardiol, 76, 1395, 10.1016/j.jacc.2020.07.047
Marui, 2014, CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions </ = 50% versus >50% (from the CREDO-Kyoto PCI/CABG Registry Cohort-2), Am J Cardiol, 114, 988, 10.1016/j.amjcard.2014.07.007
Wolff, 2017, Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: a meta-analysis, Circ Heart Fail, 10, 10.1161/CIRCHEARTFAILURE.116.003255
Gaudino, 2021, Treatment strategies in ischaemic left ventricular dysfunction: a network meta-analysis, Eur J Cardiothorac Surg, 59, 293, 10.1093/ejcts/ezaa319
Genereux, 2017, Staging classification of aortic stenosis based on the extent of cardiac damage, Eur Heart J, 38, 3351, 10.1093/eurheartj/ehx381
Vahanian, 2021, 2021 ESC/EACTS Guidelines for the management of valvular heart disease, Eur Heart J, 10.1093/eurheartj/ehab626
Leon, 2010, PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery, N Engl J Med, 363, 1597, 10.1056/NEJMoa1008232
Smith, 2011, PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients, N Engl J Med, 364, 2187, 10.1056/NEJMoa1103510
Adams, 2014, US CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis, N Engl J Med, 370, 1790, 10.1056/NEJMoa1400590
Popma, 2014, CoreValve United States Clinical Investigators. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery, J Am Coll Cardiol, 63, 1972, 10.1016/j.jacc.2014.02.556
Leon, 2016, Transcatheter or surgical aortic-valve replacement in intermediate-risk patients, N Engl J Med, 374, 1609, 10.1056/NEJMoa1514616
Reardon, 2017, Surgical or transcatheter aortic-valve replacement in intermediate-risk patients, N Engl J Med, 376, 1321, 10.1056/NEJMoa1700456
Popma, 2019, Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients, N Engl J Med, 380, 1706, 10.1056/NEJMoa1816885
Mack, 2019, PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients, N Engl J Med, 380, 1695, 10.1056/NEJMoa1814052
Elder, 2011, The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study, J Am Coll Cardiol, 58, 2084, 10.1016/j.jacc.2011.07.043
Chaliki, 2002, Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function, Circulation, 106, 2687, 10.1161/01.CIR.0000038498.59829.38
Tornos, 2006, Long-term outcome of surgically treated aortic regurgitation: influence of guideline adherence toward early surgery, J Am Coll Cardiol, 47, 1012, 10.1016/j.jacc.2005.10.049
Yoon, 2017, Transcatheter aortic valve replacement in pure native aortic valve regurgitation, J Am Coll Cardiol, 70, 2752, 10.1016/j.jacc.2017.10.006
Feldman, 2011, Percutaneous repair or surgery for mitral regurgitation, N Engl J Med, 364, 1395, 10.1056/NEJMoa1009355
Tamargo, 2020, Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction, Eur J Heart Fail, 22, 489, 10.1002/ejhf.1699
Dziadzko, 2018, Outcome and undertreatment of mitral regurgitation: a community cohort study, Lancet, 391, 960, 10.1016/S0140-6736(18)30473-2
Goliasch, 2018, Refining the prognostic impact of functional mitral regurgitation in chronic heart failure, Eur Heart J, 39, 39, 10.1093/eurheartj/ehx402
Bertrand, 2017, Exercise dynamics in secondary mitral regurgitation: pathophysiology and therapeutic implications, Circulation, 135, 297, 10.1161/CIRCULATIONAHA.116.025260
Obadia, 2018, Percutaneous repair or medical treatment for secondary mitral regurgitation, N Engl J Med, 379, 2297, 10.1056/NEJMoa1805374
Iung, 2019, Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years, Eur J Heart Fail, 21, 1619, 10.1002/ejhf.1616
Stone, 2018, Transcatheter mitral-valve repair in patients with heart failure, N Engl J Med, 379, 2307, 10.1056/NEJMoa1806640
Senni, 2019, Treatment of functional mitral regurgitation in chronic heart failure: can we get a ‘proof of concept’ from the MITRA-FR and COAPT trials?, Eur J Heart Fail, 21, 852, 10.1002/ejhf.1491
Grayburn, 2019, Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials, JACC Cardiovasc Imaging, 12, 353, 10.1016/j.jcmg.2018.11.006
Coats, 2021, The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, Eur Heart J, 42, 1254, 10.1093/eurheartj/ehab086
Adamo, 2021, COAPT-like profile predicts long-term outcomes in patients with secondary mitral regurgitation undergoing MitraClip implantation, JACC Cardiovasc Interv, 14, 15, 10.1016/j.jcin.2020.09.050
Godino, 2020, MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry, J Heart Lung Transplant, 39, 1353, 10.1016/j.healun.2020.09.005
Witte, 2019, The REDUCE FMR trial: a randomized sham-controlled study of percutaneous mitral annuloplasty in functional mitral regurgitation, JACC Heart Fail, 7, 945, 10.1016/j.jchf.2019.06.011
Geyer, 2020, Association of transcatheter direct mitral annuloplasty with acute anatomic, haemodynamic, and clinical outcomes in severe mitral valve regurgitation, ESC Heart Fail, 7, 3336, 10.1002/ehf2.12957
Giallauria, 2020, Individual patient data meta-analysis of the effects of the CARILLON® mitral contour system, ESC Heart Fail, 7, 3383, 10.1002/ehf2.13125
Lipiecki, 2020, Long-term prognosis of patients treated by coronary sinus-based percutaneous annuloplasty: single centre experience, ESC Heart Fail, 7
Ruf, 2020, Transcatheter indirect mitral annuloplasty induces annular and left atrial remodelling in secondary mitral regurgitation, ESC Heart Fail, 7, 1400, 10.1002/ehf2.12710
Sorajja, 2019, Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients, J Am Coll Cardiol, 73, 1250, 10.1016/j.jacc.2018.12.066
Zack, 2017, National trends and outcomes in isolated tricuspid valve surgery, J Am Coll Cardiol, 70, 2953, 10.1016/j.jacc.2017.10.039
Taramasso, 2019, Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation, J Am Coll Cardiol, 74, 2998, 10.1016/j.jacc.2019.09.028
Rapsomaniki, 2014, Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people, Lancet, 383, 1899, 10.1016/S0140-6736(14)60685-1
Cohn, 2003, Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON), Eur J Heart Fail, 5, 659, 10.1016/S1388-9842(03)00163-6
Kato, 2008, Exaggerated hypertensive response to exercise in patients with diastolic heart failure, Hypertens Res, 31, 679, 10.1291/hypres.31.679
Uijl, 2021, Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction, Eur J Heart Fail, 23, 10.1002/ejhf.2169
Thomopoulos, 2018, Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis, J Hypertens, 36, 1637, 10.1097/HJH.0000000000001777
Vaduganathan, 2021, Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy, Eur J Heart Fail, 23, 384, 10.1002/ejhf.1971
Fagard, 2009, Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies, Hypertension, 54, 1084, 10.1161/HYPERTENSIONAHA.109.136655
Cautela, 2020, Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients, Eur J Heart Fail, 22, 1357, 10.1002/ejhf.1835
Kang, 2017, Risk of stroke in congestive heart failure with and without atrial fibrillation, Int J Cardiol, 248, 182, 10.1016/j.ijcard.2017.07.056
Abdul-Rahim, 2015, Investigators of the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA), GISSI-Heart Failure (GISSI-HF) Committees and Investigators. Risk of stroke in chronic heart failure patients without atrial fibrillation: analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) trials, Circulation, 131, 1486, 10.1161/CIRCULATIONAHA.114.013760
Abdul-Rahim, 2017, Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Preserved (CHARM-Preserved) and the Irbesartan in Heart Failure with Preserved Systolic Function (I-Preserve) Steering Committees. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials, Eur Heart J, 38, 742
Mehra, 2019, A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial, Eur Heart J, 40, 3593, 10.1093/eurheartj/ehz427
Kotecha, 2016, Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes, Int J Cardiol, 203, 660, 10.1016/j.ijcard.2015.10.220
Adelborg, 2017, Risk of stroke in patients with heart failure: a population-based 30-year cohort study, Stroke, 48, 1161, 10.1161/STROKEAHA.116.016022
Witt, 2006, Ischemic stroke after heart failure: a community-based study, Am Heart J, 152, 102, 10.1016/j.ahj.2005.10.018
Homma, 2012, Warfarin and aspirin in patients with heart failure and sinus rhythm, N Engl J Med, 366, 1859, 10.1056/NEJMoa1202299
Hopper, 2013, Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythm, Eur J Heart Fail, 15, 69, 10.1093/eurjhf/hfs171
Bauersachs, 2019, Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy, Eur J Heart Fail, 21, 827, 10.1002/ejhf.1493
Singh, 2021, StatPearls [Internet].
Subahi, 2017, Isolated left ventricular non-compaction (LVNC) and recurrent strokes: to anticoagulate or not to anticoagulate, that is the question, BMJ Case Rep, 2017
Seferovic, 2018, Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 20, 853, 10.1002/ejhf.1170
Seferovic, 2020, European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure, Eur J Heart Fail, 22, 196, 10.1002/ejhf.1673
Cosentino, 2020, Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial, Circulation, 142, 2205, 10.1161/CIRCULATIONAHA.120.050255
McGuire, 2021, Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis, JAMA Cardiol, 6, 148, 10.1001/jamacardio.2020.4511
Seferovic, 2019, Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 21, 1169, 10.1002/ejhf.1531
Eurich, 2013, Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients, Circ Heart Fail, 6, 395, 10.1161/CIRCHEARTFAILURE.112.000162
Andersson, 2010, Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study, Diabetologia, 53, 2546, 10.1007/s00125-010-1906-6
Scirica, 2013, SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, N Engl J Med, 369, 1317, 10.1056/NEJMoa1307684
Zannad, 2015, EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial, Lancet, 385, 2067, 10.1016/S0140-6736(14)62225-X
Green, 2015, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes, N Engl J Med, 373, 232, 10.1056/NEJMoa1501352
Rosenstock, 2019, Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial, JAMA, 321, 69, 10.1001/jama.2018.18269
McMurray, 2018, VIVIDD Trial Committees and Investigators. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial, JACC Heart Fail, 6, 8, 10.1016/j.jchf.2017.08.004
Sinha, 2019, Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure, Diabetes Res Clin Pract, 150, 8, 10.1016/j.diabres.2019.02.014
Savarese, 2016, Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis, Int J Cardiol, 220, 595, 10.1016/j.ijcard.2016.06.208
Kristensen, 2019, Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials, Lancet Diabetes Endocrinol, 7, 776, 10.1016/S2213-8587(19)30249-9
Jorsal, 2017, Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial, Eur J Heart Fail, 19, 69, 10.1002/ejhf.657
Margulies, 2016, Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial, JAMA, 316, 500, 10.1001/jama.2016.10260
Gerstein, 2018, Effect of basal insulin glargine on first and recurrent episodes of heart failure hospitalization: the ORIGIN trial (Outcome Reduction With Initial Glargine Intervention), Circulation, 137, 88, 10.1161/CIRCULATIONAHA.117.030924
Cosmi, 2018, Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes, Eur J Heart Fail, 20, 888, 10.1002/ejhf.1146
Shen, 2019, Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction, Eur J Heart Fail, 21, 974, 10.1002/ejhf.1535
Tzoulaki, 2009, Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database, BMJ, 339, b4731, 10.1136/bmj.b4731
Roumie, 2017, Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study, J Am Heart Assoc, 6, 10.1161/JAHA.116.005379
Lago, 2007, Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials, Lancet, 370, 1129, 10.1016/S0140-6736(07)61514-1
Vargas-Uricoechea, 2017, Thyroid dysfunction and heart failure: mechanisms and associations, Curr Heart Fail Rep, 14, 48, 10.1007/s11897-017-0312-5
Kannan, 2018, Thyroid dysfunction in heart failure and cardiovascular outcomes, Circ Heart Fail, 11, e005266, 10.1161/CIRCHEARTFAILURE.118.005266
Sato, 2019, Low T3 syndrome is associated with high mortality in hospitalized patients with heart failure, J Card Fail, 25, 195, 10.1016/j.cardfail.2019.01.007
Stott, 2017, Thyroid hormone therapy for older adults with subclinical hypothyroidism, N Engl J Med, 376, 2534, 10.1056/NEJMoa1603825
Feller, 2018, Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis, JAMA, 320, 1349, 10.1001/jama.2018.13770
Packer, 2020, Characterization of the inflammatory-metabolic phenotype of heart failure and a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease, Eur J Heart Fail, 22, 1551, 10.1002/ejhf.1902
Obokata, 2017, Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction, Circulation, 136, 6, 10.1161/CIRCULATIONAHA.116.026807
Rao, 2020, Regional adiposity and heart failure with preserved ejection fraction, Eur J Heart Fail, 22, 1540, 10.1002/ejhf.1956
Carbone, 2017, Obesity and heart failure: focus on the obesity paradox, Mayo Clin Proc, 92, 266, 10.1016/j.mayocp.2016.11.001
Horwich, 2018, Obesity and the obesity paradox in heart failure, Prog Cardiovasc Dis, 61, 151, 10.1016/j.pcad.2018.05.005
Adamopoulos, 2011, Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study, Eur J Heart Fail, 13, 200, 10.1093/eurjhf/hfq159
Zamora, 2016, No benefit from the obesity paradox for diabetic patients with heart failure, Eur J Heart Fail, 18, 851, 10.1002/ejhf.576
Piepoli, 2016, Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the MECKI Score Research Group, Eur J Heart Fail, 18, 545, 10.1002/ejhf.534
Streng, 2018, Waist-to-hip ratio and mortality in heart failure, Eur J Heart Fail, 20, 1269, 10.1002/ejhf.1244
Carbone, 2018, Obesity and mortality risk in heart failure: when adipose tissue distribution matters, Eur J Heart Fail, 20, 1278, 10.1002/ejhf.1279
Packer, 2020, Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment, Eur J Heart Fail, 22, 214, 10.1002/ejhf.1646
Vitale, 2019, Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure, Eur J Heart Fail, 21, 1299, 10.1002/ejhf.1611
Denfeld, 2017, The prevalence of frailty in heart failure: a systematic review and meta-analysis, Int J Cardiol, 236, 283, 10.1016/j.ijcard.2017.01.153
Bielecka-Dabrowa, 2020, Cachexia, muscle wasting, and frailty in cardiovascular disease, Eur J Heart Fail, 22, 2314, 10.1002/ejhf.2011
Khan, 2013, Frailty and risk for heart failure in older adults: the health, aging, and body composition study, Am Heart J, 166, 887, 10.1016/j.ahj.2013.07.032
Woods, 2005, Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study, J Am Geriatr Soc, 53, 1321, 10.1111/j.1532-5415.2005.53405.x
Vidan, 2016, Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure, Eur J Heart Fail, 18, 869, 10.1002/ejhf.518
Dewan, 2020, The prevalence and importance of frailty in heart failure with reduced ejection fraction -- an analysis of PARADIGM-HF and ATMOSPHERE, Eur J Heart Fail, 22, 2123, 10.1002/ejhf.1832
Sanders, 2018, The frailty syndrome and outcomes in the TOPCAT trial, Eur J Heart Fail, 20, 1570, 10.1002/ejhf.1308
Loncar, 2016, Cardiac cachexia: hic et nunc, J Cachexia Sarcopenia Muscle, 7, 246, 10.1002/jcsm.12118
von Haehling, 2009, Cardiac cachexia: a systematic overview, Pharmacol Ther, 121, 227, 10.1016/j.pharmthera.2008.09.009
Anker, 2019, Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review, J Cachexia Sarcopenia Muscle, 10, 22, 10.1002/jcsm.12402
Bauer, 2019, Sarcopenia: a time for action. An SCWD position paper, J Cachexia Sarcopenia Muscle, 10, 956, 10.1002/jcsm.12483
Ameri, 2018, Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge, Eur J Heart Fail, 20, 879, 10.1002/ejhf.1165
Fonseca, 2020, Discriminating sarcopenia in overweight/obese male patients with heart failure: the influence of body mass index, ESC Heart Fail, 7, 84
Emami, 2018, Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF, Eur J Heart Fail, 20, 1580, 10.1002/ejhf.1304
Fulster, 2013, Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF, Eur Heart J, 34, 512, 10.1093/eurheartj/ehs381
Springer, 2017, Muscle wasting and sarcopenia in heart failure and beyond: update 2017, ESC Heart Fail, 4, 492, 10.1002/ehf2.12237
von Haehling, 2017, Muscle wasting and cachexia in heart failure: mechanisms and therapies, Nat Rev Cardiol, 14, 323, 10.1038/nrcardio.2017.51
Caminiti, 2009, Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study, J Am Coll Cardiol, 54, 919, 10.1016/j.jacc.2009.04.078
Anand, 2018, Anemia and iron deficiency in heart failure: current concepts and emerging therapies, Circulation, 138, 80, 10.1161/CIRCULATIONAHA.118.030099
Iorio, 2018, Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study, Eur J Heart Fail, 20, 1257, 10.1002/ejhf.1202
Okonko, 2011, Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival, J Am Coll Cardiol, 58, 1241, 10.1016/j.jacc.2011.04.040
McDonagh, 2018, Comin-Colet J. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice, Eur J Heart Fail, 20, 1664, 10.1002/ejhf.1305
Cappellini, 2017, Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management, Am J Hematol, 92, 1068, 10.1002/ajh.24820
Lopez, 2016, Peyrin-Biroulet L. Iron deficiency anaemia, Lancet, 387, 907, 10.1016/S0140-6736(15)60865-0
Sierpinski, High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality, Eur J Heart Fail
Rocha, 2018, The burden of iron deficiency in heart failure: therapeutic approach, J Am Coll Cardiol, 71, 782, 10.1016/j.jacc.2017.12.027
Klip, 2013, Iron deficiency in chronic heart failure: an international pooled analysis, Am Heart J, 165, 575, 10.1016/j.ahj.2013.01.017
Jankowska, 2010, Iron deficiency: an ominous sign in patients with systolic chronic heart failure, Eur Heart J, 31, 1872, 10.1093/eurheartj/ehq158
von Haehling, 2015, Iron deficiency and cardiovascular disease, Nat Rev Cardiol, 12, 659, 10.1038/nrcardio.2015.109
Stugiewicz, 2016, The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications, Eur J Heart Fail, 18, 762, 10.1002/ejhf.467
Jankowska, 2013, Iron status in patients with chronic heart failure, Eur Heart J, 34, 827, 10.1093/eurheartj/ehs377
Swedberg, 2013, Treatment of anemia with darbepoetin alfa in systolic heart failure, N Engl J Med, 368, 1210, 10.1056/NEJMoa1214865
Anker, 2009, Ferric carboxymaltose in patients with heart failure and iron deficiency, N Engl J Med, 361, 2436, 10.1056/NEJMoa0908355
Comin-Colet, 2013, The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study, Eur Heart J, 34, 30, 10.1093/eurheartj/ehr504
Ponikowski, 2015, Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency, Eur Heart J, 36, 657, 10.1093/eurheartj/ehu385
van Veldhuisen, 2017, Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency, Circulation, 136, 1374, 10.1161/CIRCULATIONAHA.117.027497
Jankowska, 2016, Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials, Eur J Heart Fail, 18, 786, 10.1002/ejhf.473
Anker, 2018, Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis, Eur J Heart Fail, 20, 125, 10.1002/ejhf.823
Filippatos, 2013, Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial, Eur J Heart Fail, 15, 1267, 10.1093/eurjhf/hft099
von Haehling, 2019, Iron deficiency in heart failure: an overview, JACC Heart Fail, 7, 36, 10.1016/j.jchf.2018.07.015
Lewis, 2017, NHLBI Heart Failure Clinical Research Network. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial, JAMA, 317, 1958, 10.1001/jama.2017.5427
Mullens, 2020, Evaluation of kidney function throughout the heart failure trajectory -- a position statement from the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 22, 584, 10.1002/ejhf.1697
Ter Maaten, 2016, Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation, Eur J Heart Fail, 18, 588, 10.1002/ejhf.497
van der Pol, 2019, Treating oxidative stress in heart failure: past, present and future, Eur J Heart Fail, 21, 425, 10.1002/ejhf.1320
Lofman, 2017, Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction, Eur J Heart Fail, 19, 1606, 10.1002/ejhf.821
Lofman, 2019, Incidence of, associations with and prognostic impact of worsening renal function in heart failure with different ejection fraction categories, Am J Cardiol, 124, 1575, 10.1016/j.amjcard.2019.07.065
Schefold, 2016, Heart failure and kidney dysfunction: epidemiology, mechanisms and management, Nat Rev Nephrol, 12, 610, 10.1038/nrneph.2016.113
Damman, 2014, Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis, Eur Heart J, 35, 455, 10.1093/eurheartj/eht386
Braunwald, 2019, Diabetes, heart failure, and renal dysfunction: the vicious circles, Prog Cardiovasc Dis, 62, 298, 10.1016/j.pcad.2019.07.003
Zannad, 2021, Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced, Circulation, 143, 310, 10.1161/CIRCULATIONAHA.120.051685
Heerspink, 2020, -CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease, N Engl J Med, 383, 1436, 10.1056/NEJMoa2024816
Metra, 2012, Dei Cas L. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function, Circ Heart Fail, 5, 54, 10.1161/CIRCHEARTFAILURE.111.963413
Testani, 2011, Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction, Circ Heart Fail, 4, 685, 10.1161/CIRCHEARTFAILURE.111.963256
Damman, 2014, Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data, J Am Coll Cardiol, 63, 853, 10.1016/j.jacc.2013.11.031
House, 2018, Management of heart failure in advancing CKD: core curriculum 2018, Am J Kidney Dis, 72, 284, 10.1053/j.ajkd.2017.12.006
Kotecha, 2019, Beta-Blockers in Heart Failure Collaborative Group. Impact of renal impairment on beta-blocker efficacy in patients with heart failure, J Am Coll Cardiol, 74, 2893, 10.1016/j.jacc.2019.09.059
Jhund, 2021, Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF, Circulation, 143, 298, 10.1161/CIRCULATIONAHA.120.050391
Boerrigter, 2008, Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate, J Card Fail, 14, 539, 10.1016/j.cardfail.2008.03.009
Roehm, 2018, Left ventricular assist devices kidney disease and dialysis, Am J Kidney Dis, 71, 257, 10.1053/j.ajkd.2017.09.019
Goldenberg, 2006, Multicenter Automatic Defibrillator Implantation Trial-II Investigators. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction, Am J Cardiol, 98, 485, 10.1016/j.amjcard.2006.03.025
Goldenberg, 2020, Competing risk analysis of ventricular arrhythmia events in heart failure patients with moderately compromised renal dysfunction, Europace, 22, 1384, 10.1093/europace/euaa146
Coiro, 2019, Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure, Eur J Heart Fail, 21, 1248, 10.1002/ejhf.1541
Teerlink, 2020, Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials, Eur J Heart Fail, 22, 2160, 10.1002/ejhf.2015
Urso, 2015, Acid-base and electrolyte abnormalities in heart failure: pathophysiology and implications, Heart Fail Rev, 20, 493, 10.1007/s10741-015-9482-y
Butler, 2018, Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists, Eur J Heart Fail, 20, 1247, 10.1002/ejhf.1217
Vardeny, 2014, Randomized Aldactone Evaluation Study (RALES) Investigators. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist, Circ Heart Fail, 7, 573, 10.1161/CIRCHEARTFAILURE.114.001104
Rossignol, 2014, Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF, Circ Heart Fail, 7, 51, 10.1161/CIRCHEARTFAILURE.113.000792
Nunez, 2018, Long-term potassium monitoring and dynamics in heart failure and risk of mortality, Circulation, 137, 1320, 10.1161/CIRCULATIONAHA.117.030576
Linde, 2019, Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK, ESC Heart Fail, 6, 280, 10.1002/ehf2.12402
Cooper, 2020, Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry, Eur J Heart Fail, 22, 1390, 10.1002/ejhf.1757
Rossignol, 2020, Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry, Eur J Heart Fail, 22, 1378, 10.1002/ejhf.1793
Ahmed, 2007, A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure, Eur Heart J, 28, 1334, 10.1093/eurheartj/ehm091
Rosano, 2018, Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology, Eur Heart J Cardiovasc Pharmacother, 4, 180, 10.1093/ehjcvp/pvy015
Ferreira, 2020, Serum potassium in the PARADIGM-HF trial, Eur J Heart Fail, 22, 2056, 10.1002/ejhf.1987
Rossignol, 2020, Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction, Eur J Heart Fail, 22, 1402, 10.1002/ejhf.1724
Desai, 2018, Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial, J Card Fail, 24, 313, 10.1016/j.cardfail.2018.03.002
Desai, 2009, Hyperkalemia in patients with heart failure: incidence, prevalence, and management, Curr Heart Fail Rep, 6, 272, 10.1007/s11897-009-0037-1
Savarese, 2019, Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction, JACC Heart Fail, 7, 65, 10.1016/j.jchf.2018.10.003
Rosano, 2019, Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate, Eur Heart J Suppl, 21, A28, 10.1093/eurheartj/suy035
Anker, 2015, Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial, Eur J Heart Fail, 17, 1050, 10.1002/ejhf.300
Pitt, 2015, Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors, Eur J Heart Fail, 17, 1057, 10.1002/ejhf.402
Trevisan, 2018, Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists, Eur J Heart Fail, 20, 1217, 10.1002/ejhf.1199
Ferreira, 2020, Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT, Eur J Heart Fail, 22, 1615, 10.1002/ejhf.1909
Volterrani, 2020, Degli Esposti L, LHUs Study Group. Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study, Eur J Heart Fail, 22, 2049, 10.1002/ejhf.2024
Pitt, 2011, Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial, Eur Heart J, 32, 820, 10.1093/eurheartj/ehq502
Pitt, 2018, Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN, ESC Heart Fail, 5, 592, 10.1002/ehf2.12292
Agarwal, 2019, Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial, Lancet, 394, 1540, 10.1016/S0140-6736(19)32135-X
Rossignol, 2020, Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure, Eur J Heart Fail, 22, 1462, 10.1002/ejhf.1860
Pitt, 2018, Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease, ESC Heart Fail, 5, 257, 10.1002/ehf2.12265
Ali, 2020, Evolution of patiromer use: a review, Curr Cardiol Rep, 22, 94, 10.1007/s11886-020-01342-w
Rodriguez, 2019, Hyponatremia in heart failure: pathogenesis and management, Curr Cardiol Rev, 15, 252, 10.2174/1573403X15666190306111812
Albert, 2013, A randomized controlled pilot study of outcomes of strict allowance of fluid therapy in hyponatremic heart failure (SALT-HF), J Card Fail, 19, 1, 10.1016/j.cardfail.2012.11.007
Dunlap, 2017, Current management of hyponatremia in acute heart failure: a report from the Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia (HN Registry), J Am Heart Assoc, 6, e005261, 10.1161/JAHA.116.005261
Konstam, 2007, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial, JAMA, 297, 1319, 10.1001/jama.297.12.1319
Felker, 2017, Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure, J Am Coll Cardiol, 69, 1399, 10.1016/j.jacc.2016.09.004
Matsue, 2017, Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction, Clin Res Cardiol, 106, 802, 10.1007/s00392-017-1122-1
Konstam, 2017, SECRET of CHF Investigators, Coordinators, and Committee Members. Short-term effects of tolvaptan in patients with acute heart failure and volume overload, J Am Coll Cardiol, 69, 1409, 10.1016/j.jacc.2016.12.035
Licata, 2003, Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects, Am Heart J, 145, 459, 10.1067/mhj.2003.166
Paterna, 2000, Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure, Eur J Heart Fail, 2, 305, 10.1016/S1388-9842(00)00094-5
Griffin, 2020, Real world use of hypertonic saline in refractory acute decompensated heart failure: a U.S. center's experience, JACC Heart Fail, 8, 199, 10.1016/j.jchf.2019.10.012
Cuthbert, 2018, Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance, Eur J Heart Fail, 20, 1426, 10.1002/ejhf.1247
Testani, 2016, Hypochloraemia is strongly and independently associated with mortality in patients with chronic heart failure, Eur J Heart Fail, 18, 660, 10.1002/ejhf.477
Marchenko, 2020, Hypochloraemia and 30 day readmission rate in patients with acute decompensated heart failure, ESC Heart Fail, 7, 903, 10.1002/ehf2.12587
Grodin, 2015, Prognostic role of serum chloride levels in acute decompensated heart failure, J Am Coll Cardiol, 66, 659, 10.1016/j.jacc.2015.06.007
Hanberg, 2016, Hypochloremia and diuretic resistance in heart failure: mechanistic insights, Circ Heart Fail, 9, 10.1161/CIRCHEARTFAILURE.116.003180
Verbrugge, 2019, Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance, Eur J Heart Fail, 21, 1415, 10.1002/ejhf.1478
Axson, 2020, Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis, Respir Res, 21, 54, 10.1186/s12931-020-1312-7
Canepa, 2018, Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry, Eur J Heart Fail, 20, 100, 10.1002/ejhf.964
Uijl, 2019, Risk factors for incident heart failure in age- and sex-specific strata: a population-based cohort using linked electronic health records, Eur J Heart Fail, 21, 1197, 10.1002/ejhf.1350
Caravita, 2016, Obstructive ventilatory disorder in heart failure--caused by the heart or the lung?, Curr Heart Fail Rep, 13, 310, 10.1007/s11897-016-0309-5
Magnussen, 2017, What can we learn from pulmonary function testing in heart failure?, Eur J Heart Fail, 19, 1222, 10.1002/ejhf.946
Canepa, 2019, Diagnostic and therapeutic gaps in patients with heart failure and chronic obstructive pulmonary disease, JACC Heart Fail, 7, 823, 10.1016/j.jchf.2019.05.009
Global Initiative for Chronic Obstructive Lung Disease
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019
Brook, 2017, Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk, Heart, 103, 1536, 10.1136/heartjnl-2016-310897
Vestbo, 2016, Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial, Lancet, 387, 1817, 10.1016/S0140-6736(16)30069-1
Hohlfeld, 2018, Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial, Lancet Respir Med, 6, 368, 10.1016/S2213-2600(18)30054-7
Pearse, 2016, Sleep-disordered breathing in heart failure, Eur J Heart Fail, 18, 353, 10.1002/ejhf.492
Cowie, 2017, Sleep disordered breathing and heart failure: what does the future hold?, JACC Heart Fail, 5, 715, 10.1016/j.jchf.2017.06.016
Cowie, 2015, Adaptive servo-ventilation for central sleep apnea in systolic heart failure, N Engl J Med, 373, 1095, 10.1056/NEJMoa1506459
Costanzo, 2016, remedé System Pivotal Trial Study Group. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial, Lancet, 388, 974, 10.1016/S0140-6736(16)30961-8
Costanzo, 2018, remedé System Pivotal Trial Study Group. Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure, Eur J Heart Fail, 20, 1746, 10.1002/ejhf.1312
Kjekshus, 2007, Rosuvastatin in older patients with systolic heart failure, N Engl J Med, 357, 2248, 10.1056/NEJMoa0706201
Tavazzi, 2008, Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1231, 10.1016/S0140-6736(08)61240-4
Al-Gobari, 2017, No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: a meta-analysis of randomized controlled trials, PLoS One, 12, e0171168, 10.1371/journal.pone.0171168
Rogers, 2014, Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA trial (Controlled Rosuvastatin Multinational Trial in Heart Failure), JACC Heart Fail, 2, 289, 10.1016/j.jchf.2013.12.007
Feinstein, 2015, Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF, Eur J Heart Fail, 17, 434, 10.1002/ejhf.247
Thanassoulis, 2010, Gout, allopurinol use, and heart failure outcomes, Arch Intern Med, 170, 1358, 10.1001/archinternmed.2010.198
Borghi, 2020, Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure, Heart Fail Rev, 25, 43, 10.1007/s10741-019-09869-z
Doehner, 2008, Uric acid in chronic heart failure--current pathophysiological concepts, Eur J Heart Fail, 10, 1269, 10.1016/j.ejheart.2008.10.005
Huang, 2014, Uric acid and risk of heart failure: a systematic review and meta-analysis, Eur J Heart Fail, 16, 15, 10.1093/eurjhf/hft132
White, 2018, Cardiovascular safety of febuxostat or allopurinol in patients with gout, N Engl J Med, 378, 1200, 10.1056/NEJMoa1710895
Hare, 2008, Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study, J Am Coll Cardiol, 51, 2301, 10.1016/j.jacc.2008.01.068
Ogino, 2010, Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study, Circ Heart Fail, 3, 73, 10.1161/CIRCHEARTFAILURE.109.868604
Givertz, 2015, NHLBI Heart Failure Clinical Research Network. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) study, Circulation, 131, 1763, 10.1161/CIRCULATIONAHA.114.014536
Verma, 2015, Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials, BMC Cardiovasc Disord, 15, 96, 10.1186/s12872-015-0068-3
Frommeyer, 2017, Colchicine increases ventricular vulnerability in an experimental whole-heart model, Basic Clin Pharmacol Toxicol, 120, 505, 10.1111/bcpt.12702
Arfe, 2016, Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study, BMJ, 354, i4857, 10.1136/bmj.i4857
Khalid, 2020, Incidence of congestive heart failure in rheumatoid arthritis: a review of literature and meta-regression analysis, ESC Heart Fail, 7, 3745, 10.1002/ehf2.12947
Mantel, 2017, Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure, J Am Coll Cardiol, 69, 1275, 10.1016/j.jacc.2016.12.033
Chung, 2003, Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial, Circulation, 107, 3133, 10.1161/01.CIR.0000077913.60364.D2
Mann, 2004, Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL), Circulation, 109, 1594, 10.1161/01.CIR.0000124490.27666.B2
Kotyla, 2018, Bimodal function of anti-TNF treatment: shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure?, Int J Mol Sci, 19, 1739, 10.3390/ijms19061739
Baumhakel, 2011, Cardiovascular risk, drugs and erectile function--a systematic analysis, Int J Clin Pract, 65, 289, 10.1111/j.1742-1241.2010.02563.x
Jaarsma, 2017, Sexual function of patients with heart failure: facts and numbers, ESC Heart Fail, 4, 3, 10.1002/ehf2.12108
Levine, 2012, Characterization of the role of nitric oxide and its clinical applications, Cardiology, 122, 55, 10.1159/000338150
Giannetta, 2014, Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials, BMC Med, 12, 185, 10.1186/s12916-014-0185-3
Angermann, 2018, Depression, anxiety, and cognitive impairment: comorbid mental health disorders in heart failure, Curr Heart Fail Rep, 15, 398, 10.1007/s11897-018-0414-8
Sbolli, 2020, Depression and heart failure: the lonely comorbidity, Eur J Heart Fail, 22, 2007, 10.1002/ejhf.1865
Jha, 2019, Screening and management of depression in patients with cardiovascular disease: JACC state-of-the-art review, J Am Coll Cardiol, 73, 1827, 10.1016/j.jacc.2019.01.041
Berkman, 2003, Enhancing Recovery in Coronary Heart Disease Patients Investigators. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial, JAMA, 289, 3106, 10.1001/jama.289.23.3106
O'Connor, 2010, Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial, J Am Coll Cardiol, 56, 692, 10.1016/j.jacc.2010.03.068
Angermann, 2016, MOOD-HF Study Investigators and Committee Members. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial, JAMA, 315, 2683, 10.1001/jama.2016.7635
de Boer, 2019, Cancer and heart disease: associations and relations, Eur J Heart Fail, 21, 1515, 10.1002/ejhf.1539
Farmakis, 2018, Anthracycline-induced cardiomyopathy: secrets and lies, Eur J Heart Fail, 20, 907, 10.1002/ejhf.1172
Zamorano, 2017, 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC), Eur J Heart Fail, 19, 9, 10.1002/ejhf.654
Lyon, 2020, Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society, Eur J Heart Fail, 22, 1945, 10.1002/ejhf.1920
Ganatra, 2019, Chimeric antigen receptor T-cell therapy for cancer and heart: JACC council perspectives, J Am Coll Cardiol, 74, 3153, 10.1016/j.jacc.2019.10.049
Lenneman, 2016, Cardio-oncology: an update on cardiotoxicity of cancer-related treatment, Circ Res, 118, 1008, 10.1161/CIRCRESAHA.115.303633
Lyon, 2018, Immune checkpoint inhibitors and cardiovascular toxicity, Lancet Oncol, 19, e447, 10.1016/S1470-2045(18)30457-1
Boekel, 2020, Heart failure after treatment for breast cancer, Eur J Heart Fail, 22, 366, 10.1002/ejhf.1620
Farmakis, 2014, Insights into onco-cardiology: atrial fibrillation in cancer, J Am Coll Cardiol, 63, 945, 10.1016/j.jacc.2013.11.026
Tromp, 2020, Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls, Eur J Heart Fail, 22, 1239, 10.1002/ejhf.1758
Hasin, 2016, Heart failure after myocardial infarction is associated with increased risk of cancer, J Am Coll Cardiol, 68, 265, 10.1016/j.jacc.2016.04.053
Banke, 2016, Incidence of cancer in patients with chronic heart failure: a long-term follow-up study, Eur J Heart Fail, 18, 260, 10.1002/ejhf.472
Meijers, 2019, Common risk factors for heart failure and cancer, Cardiovasc Res, 115, 844, 10.1093/cvr/cvz035
de Boer, 2020, Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), Eur J Heart Fail, 22, 2272, 10.1002/ejhf.2029
Selvaraj, 2018, Lack of association between heart failure and incident cancer, J Am Coll Cardiol, 71, 1501, 10.1016/j.jacc.2018.01.069
Meijers, 2018, Heart failure stimulates tumor growth by circulating factors, Circulation, 138, 678, 10.1161/CIRCULATIONAHA.117.030816
Lancellotti, 2019, Cardio-oncology services: rationale, organization, and implementation, Eur Heart J, 40, 1756, 10.1093/eurheartj/ehy453
Farmakis, 2018, How to build a cardio-oncology service?, Eur J Heart Fail, 20, 1732, 10.1002/ejhf.1336
Cardinale, 2010, Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy, J Am Coll Cardiol, 55, 213, 10.1016/j.jacc.2009.03.095
Cardinale, 2015, Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy, Circulation, 131, 1981, 10.1161/CIRCULATIONAHA.114.013777
Gulati, 2016, Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol, Eur Heart J, 37, 1671, 10.1093/eurheartj/ehw022
Pituskin, 2017, Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity, J Clin Oncol, 35, 870, 10.1200/JCO.2016.68.7830
Celutkiene, 2020, Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC), Eur J Heart Fail, 22, 1504, 10.1002/ejhf.1957
Keramida, 2019, Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients, Eur J Heart Fail, 21, 529, 10.1002/ejhf.1385
Thavendiranathan, 2021, Strain-guided management of potentially cardiotoxic cancer therapy, J Am Coll Cardiol, 77, 392, 10.1016/j.jacc.2020.11.020
Michel, 2020, Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis, Eur J Heart Fail, 22, 350, 10.1002/ejhf.1631
Pudil, 2020, Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology, Eur J Heart Fail, 22, 1966, 10.1002/ejhf.2017
Hu, 2019, Cardiovascular toxicities associated with immune checkpoint inhibitors, Cardiovasc Res, 115, 854, 10.1093/cvr/cvz026
Banke, 2018, Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial, Eur J Heart Fail, 20, 1447, 10.1002/ejhf.1168
Platz, 2018, Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality, Eur J Heart Fail, 20, 295, 10.1002/ejhf.901
Tomasoni, 2020, COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease, Eur J Heart Fail, 22, 957, 10.1002/ejhf.1871
Corrales-Medina, 2015, Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease, JAMA, 313, 264, 10.1001/jama.2014.18229
Violi, 2017, SIXTUS Study Group. Cardiovascular complications and short-term mortality risk in community-acquired pneumonia, Clin Infect Dis, 64, 1486, 10.1093/cid/cix164
Rey, 2020, Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications, Eur J Heart Fail, 22, 2205, 10.1002/ejhf.1990
Cannata, 2020, Temporal trends in decompensated heart failure and outcomes during COVID-19: a multisite report from heart failure referral centres in London, Eur J Heart Fail, 22, 2219, 10.1002/ejhf.1986
Konig, 2020, Helios Hospitals G. In-hospital care in acute heart failure during the COVID-19 pandemic: insights from the German-wide Helios hospital network, Eur J Heart Fail, 22, 2190, 10.1002/ejhf.2044
Zhang, 2020, Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 22, 941, 10.1002/ejhf.1915
Modin, 2019, Influenza vaccine in heart failure, Circulation, 139, 575, 10.1161/CIRCULATIONAHA.118.036788
Vardeny, 2016, Influenza vaccination in patients with chronic heart failure: the PARADIGM-HF trial, JACC Heart Fail, 4, 152, 10.1016/j.jchf.2015.10.012
Gotsman, 2020, Influenza vaccination and outcome in heart failure, Am J Cardiol, 128, 134, 10.1016/j.amjcard.2020.05.019
Bhatt, 2021, Clinical outcomes in patients with heart failure hospitalized with COVID-19, JACC Heart Fail, 9, 65, 10.1016/j.jchf.2020.11.003
Regitz-Zagrosek, 2018, 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy, Eur Heart J, 39, 3165, 10.1093/eurheartj/ehy340
Sliwa, 2021, Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy, Eur J Heart Fail, 23, 10.1002/ejhf.2133
Sliwa, 2020, Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry, Eur Heart J, 41, 3787, 10.1093/eurheartj/ehaa455
Davis, 2020, Peripartum cardiomyopathy: JACC state-of-the-art review, J Am Coll Cardiol, 75, 207, 10.1016/j.jacc.2019.11.014
Moulig, 2019, Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities, Eur J Heart Fail, 21, 1534, 10.1002/ejhf.1624
Stapel, 2017, Low STAT3 expression sensitizes to toxic effects of beta-adrenergic receptor stimulation in peripartum cardiomyopathy, Eur Heart J, 38, 349
Hilfiker-Kleiner, 2017, Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study, Eur Heart J, 38, 2671, 10.1093/eurheartj/ehx355
Sliwa, 2010, Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study, Circulation, 121, 1465, 10.1161/CIRCULATIONAHA.109.901496
Arbustini, 2013, The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation, J Am Coll Cardiol, 62, 2046, 10.1016/j.jacc.2013.08.1644
Hazebroek, 2015, Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis, Int J Cardiol, 199, 170, 10.1016/j.ijcard.2015.06.087
Pinto, 2016, Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases, Eur Heart J, 37, 1850, 10.1093/eurheartj/ehv727
Seferovic, 2019, Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 21, 553, 10.1002/ejhf.1461
members, 2014, ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284
Bondue, 2018, Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology, Cardiovasc Res, 114, 1287, 10.1093/cvr/cvy122
Hershberger, 2018, Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline, J Card Fail, 24, 281, 10.1016/j.cardfail.2018.03.004
Merlo, 2018, Evolving concepts in dilated cardiomyopathy, Eur J Heart Fail, 20, 228, 10.1002/ejhf.1103
Linschoten, 2017, Truncating titin (TTN) variants in chemotherapy-induced cardiomyopathy, J Card Fail, 23, 476, 10.1016/j.cardfail.2017.03.003
Wasielewski, 2014, Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy, Open Heart, 1, e000116, 10.1136/openhrt-2014-000116
Ware, 2018, Genetic etiology for alcohol-induced cardiac toxicity, J Am Coll Cardiol, 71, 2293, 10.1016/j.jacc.2018.03.462
Ware, 2016, Shared genetic predisposition in peripartum and dilated cardiomyopathies, N Engl J Med, 374, 233, 10.1056/NEJMoa1505517
van Spaendonck-Zwarts, 2014, Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy, Eur Heart J, 35, 2165, 10.1093/eurheartj/ehu050
Choi, 2018, DiscovEHR study and the NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium. Association between titin loss-of-function variants and early-onset atrial fibrillation, JAMA, 320, 2354, 10.1001/jama.2018.18179
Hazebroek, 2018, Prevalence of pathogenic gene mutations and prognosis do not differ in isolated left ventricular dysfunction compared with dilated cardiomyopathy, Circ Heart Fail, 11, e004682, 10.1161/CIRCHEARTFAILURE.117.004682
Leone, 2012, 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology, Cardiovasc Pathol, 21, 245, 10.1016/j.carpath.2011.10.001
Halliday, 2021, Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED-HF, Eur J Heart Fail, 23, 293, 10.1002/ejhf.2063
Olivotto, 2020, EXPLORER-HCM Study Investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 396, 759, 10.1016/S0140-6736(20)31792-X
Cadrin-Tourigny, 2019, A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy, Eur Heart J, 40, 1850, 10.1093/eurheartj/ehz103
Leren, 2017, Combination of ECG and echocardiography for identification of arrhythmic events in early ARVC, JACC Cardiovasc Imaging, 10, 503, 10.1016/j.jcmg.2016.06.011
Towbin, 2019, HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy, Heart Rhythm, 16, e301, 10.1016/j.hrthm.2019.05.007
Kristensen, 2019, Risk models for prediction of implantable cardioverter-defibrillator benefit: insights from the DANISH trial, JACC Heart Fail, 7, 717, 10.1016/j.jchf.2019.03.019
Corrado, 2015, Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement, Eur Heart J, 36, 3227
Elliott, 2019, Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report, Eur J Heart Fail, 21, 955, 10.1002/ejhf.1534
Mazzarotto, 2020, Reevaluating the genetic contribution of monogenic dilated cardiomyopathy, Circulation, 141, 387, 10.1161/CIRCULATIONAHA.119.037661
Caforio, 2013, Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, 34, 10.1093/eurheartj/eht210
Heymans, 2016, The quest for new approaches in myocarditis and inflammatory cardiomyopathy, J Am Coll Cardiol, 68, 2348, 10.1016/j.jacc.2016.09.937
Tschope, 2021, Myocarditis and inflammatory cardiomyopathy: current evidence and future directions, Nat Rev Cardiol, 18, 169, 10.1038/s41569-020-00435-x
Wahbi, 2019, Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies, Circulation, 140, 293, 10.1161/CIRCULATIONAHA.118.039410
Martinez, 2019, Chagas disease and heart failure: an expanding issue worldwide, Eur Cardiol, 14, 82, 10.15420/ecr.2018.30.2
Ommen, 2020, 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, Circulation, 142, e533
Walsh, 2019, Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy, Genome Med, 11, 5, 10.1186/s13073-019-0616-z
Ingles, 2019, Evaluating the clinical validity of hypertrophic cardiomyopathy genes, Circ Genom Precis Med, 12, e002460, 10.1161/CIRCGEN.119.002460
Thomson, 2019, Analysis of 51 proposed hypertrophic cardiomyopathy genes from genome sequencing data in sarcomere negative cases has negligible diagnostic yield, Genet Med, 21, 1576, 10.1038/s41436-018-0375-z
Tuohy, 2020, Hypertrophic cardiomyopathy: the future of treatment, Eur J Heart Fail, 22, 228, 10.1002/ejhf.1715
O'Mahony, 2019, Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis, Heart, 105, 623
O'Mahony, 2018, International external validation study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM), Circulation, 137, 1015, 10.1161/CIRCULATIONAHA.117.030437
O'Mahony, 2014, A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD), Eur Heart J, 35, 2010, 10.1093/eurheartj/eht439
Brignole, 2018, ESC Guidelines for the diagnosis and management of syncope, Eur Heart J, 39, 1883, 10.1093/eurheartj/ehy037
Marcus, 2010, Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria, Circulation, 121, 1533, 10.1161/CIRCULATIONAHA.108.840827
Corrado, 2020, Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis, Eur Heart J, 41, 1414, 10.1093/eurheartj/ehz669
Reichl, 2018, Desmoplakin variant-associated arrhythmogenic cardiomyopathy presenting as acute myocarditis, Circ Genom Precis Med, 11, e002373, 10.1161/CIRCGEN.118.002373
Lopez-Ayala, 2015, Genetics of myocarditis in arrhythmogenic right ventricular dysplasia, Heart Rhythm, 12, 766, 10.1016/j.hrthm.2015.01.001
Pelliccia, 2019, Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC), Eur Heart J, 40, 19, 10.1093/eurheartj/ehy730
Sedaghat-Hamedani, 2017, Clinical genetics and outcome of left ventricular non-compaction cardiomyopathy, Eur Heart J, 38, 3449, 10.1093/eurheartj/ehx545
Towbin, 2015, Left ventricular non-compaction cardiomyopathy, Lancet, 386, 813, 10.1016/S0140-6736(14)61282-4
Towbin, 2017, Cardiomyopathies due to left ventricular noncompaction, mitochondrial and storage diseases, and inborn errors of metabolism, Circ Res, 121, 838, 10.1161/CIRCRESAHA.117.310987
Reddy, 2020, Left atrial myopathy in heart failure with preserved ejection fraction, Eur J Heart Fail, 22, 486, 10.1002/ejhf.1688
Reddy, 2018, High prevalence of occult heart failure with preserved ejection fraction among patients with atrial fibrillation and dyspnea, Circulation, 137, 534, 10.1161/CIRCULATIONAHA.117.030093
Packer, 2020, Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy, Circulation, 141, 4, 10.1161/CIRCULATIONAHA.119.042996
To, 2011, Clinical utility of multimodality LA imaging: assessment of size, function, and structure, JACC Cardiovasc Imaging, 4, 788, 10.1016/j.jcmg.2011.02.018
Farmakis, 2020, High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population, Eur Heart J, 41, 4050, 10.1093/eurheartj/ehaa083
Westermann, 2017, High-sensitivity assays for troponin in patients with cardiac disease, Nat Rev Cardiol, 14, 472, 10.1038/nrcardio.2017.48
Santema, 2018, Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction, Eur Heart J, 39, 3867, 10.1093/eurheartj/ehy421
Richards, 2013, Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart, Failure). JACC Heart Fail, 1, 192, 10.1016/j.jchf.2013.02.004
Kamel, 2019, The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: rationale and methods, Int J Stroke, 14, 207, 10.1177/1747493018799981
Zelniker, 2020, Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial, Circulation, 141, 1227, 10.1161/CIRCULATIONAHA.119.044183
Global Burden of Disease Study Collaborators, 2015, Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013, Lancet, 386, 743, 10.1016/S0140-6736(15)60692-4
Cooper, 2014, The global burden of myocarditis: part 1: a systematic literature review for the Global Burden of Diseases, Injuries, and Risk Factors 2010 study, Glob Heart, 9, 121, 10.1016/j.gheart.2014.01.007
Merken, 2018, Immunosuppressive therapy improves both short- and long-term prognosis in patients with virus-negative nonfulminant inflammatory cardiomyopathy, Circ Heart Fail, 11, e004228, 10.1161/CIRCHEARTFAILURE.117.004228
Ammirati, 2020, Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document, Circ Heart Fail, 13, e007405, 10.1161/CIRCHEARTFAILURE.120.007405
Grigoratos, 2019, Diagnostic and prognostic role of cardiac magnetic resonance in acute myocarditis, Heart Fail Rev, 24, 81, 10.1007/s10741-018-9724-x
Ferreira, 2018, Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations, J Am Coll Cardiol, 72, 3158, 10.1016/j.jacc.2018.09.072
Birnie, 2016, Beanlands RS. Cardiac sarcoidosis, J Am Coll Cardiol, 68, 411, 10.1016/j.jacc.2016.03.605
Bang, 2021, Management of patients with giant cell myocarditis: JACC review topic of the week, J Am Coll Cardiol, 77, 1122, 10.1016/j.jacc.2020.11.074
Sinagra, 2021, Viral presence-guided immunomodulation in lymphocytic myocarditis: an update, Eur J Heart Fail, 23, 211, 10.1002/ejhf.1969
Gannon, 2019, State of the art: evaluation and prognostication of myocarditis using cardiac MRI, J Magn Reson Imaging, 49, e122, 10.1002/jmri.26611
Maisch, 2004, Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins, Herz, 29, 624, 10.1007/s00059-004-2628-7
Kociol, 2020, Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association, Circulation, 141, e69, 10.1161/CIR.0000000000000745
Felix, 2000, Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study, J Am Coll Cardiol, 35, 1590, 10.1016/S0735-1097(00)00568-4
Bajaj, 2020, Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature, ESC Heart Fail, 7, 1319, 10.1002/ehf2.12681
Martinez-Naharro, 2018, Cardiac amyloidosis, Clin Med (Lond), 18, s30, 10.7861/clinmedicine.18-2-s30
Ruberg, 2019, Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review, J Am Coll Cardiol, 73, 2872, 10.1016/j.jacc.2019.04.003
Gonzalez-Lopez, 2015, Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction, Eur Heart J, 36, 2585, 10.1093/eurheartj/ehv338
Helder, 2014, Impact of incidental amyloidosis on the prognosis of patients with hypertrophic cardiomyopathy undergoing septal myectomy for left ventricular outflow tract obstruction, Am J Cardiol, 114, 1396, 10.1016/j.amjcard.2014.07.058
Treibel, 2016, Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement, Circ Cardiovasc Imaging, 9, 10.1161/CIRCIMAGING.116.005066
Cavalcante, 2017, Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis, J Cardiovasc Magn Reson, 19, 98, 10.1186/s12968-017-0415-x
Castano, 2017, Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement, Eur Heart J, 38, 2879, 10.1093/eurheartj/ehx350
Nitsche, 2020, Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome, Eur J Heart Fail, 22, 1852, 10.1002/ejhf.1756
Garcia-Pavia, 2021, Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur J Heart Fail, 23, 512, 10.1002/ejhf.2140
Boldrini, 2020, Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis, JACC Cardiovasc Imaging, 13, 909, 10.1016/j.jcmg.2019.10.011
Gillmore, 2016, Nonbiopsy diagnosis of cardiac transthyretin amyloidosis, Circulation, 133, 2404, 10.1161/CIRCULATIONAHA.116.021612
Zhao, 2016, Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis, BMC Cardiovasc Disord, 16, 129, 10.1186/s12872-016-0311-6
Bhuiyan, 2011, Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS), Circ Heart Fail, 4, 121, 10.1161/CIRCHEARTFAILURE.109.910455
Cheung, 2020, Arrhythmias in cardiac amyloidosis: challenges in risk stratification and treatment, Can J Cardiol, 36, 416, 10.1016/j.cjca.2019.11.039
Maurer, 2018, ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy, N Engl J Med, 379, 1007, 10.1056/NEJMoa1805689
Damy, 2021, Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study, Eur J Heart Fail, 23, 277, 10.1002/ejhf.2027
Solomon, 2019, Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis, Circulation, 139, 431, 10.1161/CIRCULATIONAHA.118.035831
Suhr, 2015, Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study, Orphanet J Rare Dis, 10, 109, 10.1186/s13023-015-0326-6
Rosenblum, 2018, TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis, Circ Heart Fail, 11, 10.1161/CIRCHEARTFAILURE.117.004769
Kremastinos, 2011, Iron overload cardiomyopathy in clinical practice, Circulation, 124, 2253, 10.1161/CIRCULATIONAHA.111.050773
Farmakis, 2017, Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, and management, Eur J Heart Fail, 19, 479, 10.1002/ejhf.708
Aessopos, 2005, Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia, Chest, 127, 1523, 10.1378/chest.127.5.1523
Farmakis, 2011, Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked, Circulation, 123, 1227, 10.1161/CIRCULATIONAHA.110.988089
Baumgartner, 2021, 2020 ESC Guidelines for the management of adult congenital heart disease, Eur Heart J, 42, 563, 10.1093/eurheartj/ehaa554
Diller, 2015, Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre, Circulation, 132, 2118, 10.1161/CIRCULATIONAHA.115.017202
Budts, 2016, Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology, Eur Heart J, 37, 1419, 10.1093/eurheartj/ehv741
Lluri, 2019, Early experience with sacubitril/valsartan in adult patients with congenital heart disease, World J Pediatr Congenit Heart Surg, 10, 292, 10.1177/2150135119825599
Appadurai, 2020, Sacubitril/valsartan in adult congenital heart disease patients with chronic heart failure -- a single centre case series and call for an international registry, Heart Lung Circ, 29, 137, 10.1016/j.hlc.2018.12.003
Maurer, 2020, Sacubitril/valsartan for heart failure in adults with complex congenital heart disease, Int J Cardiol, 300, 137, 10.1016/j.ijcard.2019.06.031
Van De Bruaene, 2018, Management of acute heart failure in adult patients with congenital heart disease, Heart Fail Rev, 23, 1, 10.1007/s10741-017-9664-x
Minchin, 2018, Quality of care in the United Kingdom after removal of financial incentives, N Engl J Med, 379, 948, 10.1056/NEJMsa1801495
Song, 2019, Health care spending, utilization, and quality 8 years into global payment, N Engl J Med, 381, 252, 10.1056/NEJMsa1813621
Aktaa, 2020, European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes, Eur Heart J Qual Care Clin Outcomes, 10.1093/ehjqcco/qcaa069
Arbelo, 2021, Quality indicators for the care and outcomes of adults with atrial fibrillation, Europace, 23, 494, 10.1093/europace/euaa253
Schiele, 2021, 2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group, Eur Heart J Acute Cardiovasc Care, 10, 224, 10.1093/ehjacc/zuaa037
Collet, 2021, 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, Eur Heart J, 42, 1289, 10.1093/eurheartj/ehaa575